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ABSTRACT
Essential hypertension and hyperlipidaemia co-segregate in the population and act synergistically in
increasing coronary heart disease. Using invasive procedures such as brachial artery infusion of drugs,
functional abnormalities of the vascular endothelium have been observed in forearm resistance vessels
in essential hypertension, and in hypercholesterolaemia. This 'endothelial dysfunction' has been
attributed, at least in part, to impaired generation of nitric oxide. However, it is unclear whether this
dysfunction is confined to nitric oxide in the forearm vascular bed, or whether other mediators and
other microvessels are involved. Hypertension is characterised by increased peripheral vascular
resistance, which may be due to functional or structural abnormalities in the microcirculation,
particularly affecting pre-capillary vessels which make the greatest contribution to vascular resistance.
However, from studies in established hypertension it is not possible to ascertain whether
microvascular abnormalities are a cause or consequence of the rise in blood pressure (see below).
This thesis, therefore, aims (i) to examine the importance of nitric oxide in maintaining basal vascular
tone and in the control of blood pressure, and to investigate the physiological role of nitric oxide in
the human skin microcirculation; (ii) to establish the non-invasive technique of drug iontophoresis
combined with laser Doppler fluximetry for assessing endothelial function in dermal microvessels in
health, examining the principle mediators involved; (iii) to recruit patients with endothelial
dysfunction, to determine whether microvascular abnormalities are present and measurable in the
dermis using iontophoresis; (iv) to examine whether functional and/or structural abnormalities in the
microcirculation are a cause or consequence of hypertension.
Inhibition of nitric oxide synthase with systemic administration of l-A^-monomethyl-arginine
(l-NMMA) increased blood pressure and substantially increased peripheral vascular resistance,
emphasising the importance of nitric oxide in the maintenance of basal vascular tone. This led to an
investigation of the role of nitric oxide at the microvascular level - the seat of greatest contribution to
peripheral resistance. Using local brachial artery infusion of l-NMMA, tissue-specific differences in
response suggested a selective role for nitric oxide in microvessels. To investigate further the role of
nitric oxide and other mediators involved in microvascular function in vivo, the non-invasive technique
of drug iontophoresis was used in combination with brachial artery infusion of l-NMMA and
noradrenaline. Despite substantial reductions in forearm blood flow caused by these drugs, no
differences were observed in dermal blood flow. However, aspirin, which blocks prostanoid synthesis
via the cyclo-oxygenase pathway, inhibited the dermal response to acetylcholine (ACh). Thus,
iontophoresis measured prostanoid-mediated cholinergic vasodilatation in human dermal vessels. With
the pharmacological mechanisms of iontophoretic drug delivery emerging, the technique was extended
to investigate endothelial function in 10 hypercholesterolaemic patients compared with 10 matched
controls. In the patients, forearm vasodilatation was impaired with ACh but not with the endothelium-
independent vasodilator, sodium nitroprusside (SNP). In contrast, dermal vasodilatation was impaired
with SNP and not with ACh. In the presence of aspirin, in hypercholesterolaemic patients, forearm
vasodilatation to ACh was partially restored, but dermal vasodilatation to ACh was impaired. Aspirin
did not affect SNP responses. Therefore, impaired stimulated nitric oxide generation was confirmed in
forearm resistance vessels in hypercholesterolaemic patients. In dermal microvessels in these patients,
reduced smooth muscle sensitivity to nitric oxide was observed, and an enhanced, possibly
compensatory, role for prostanoid vasodilators. To identify the likely importance of microvascular
abnormalities in determining the familial risk of essential hypertension, subjects were recruited from
an epidemiological model which identifies young people with contrasting predisposition to high blood
pressure. In this model, subjects widi a predisposition to high blood pressure which was familial were
found to have structural rarefaction with a substantial increase in minimum vascular resistance in
dermal microvessels. These structural abnormalities suggest that capillary rarefaction is a cause rather
than a consequence of essential hypertension.
As hypertension and hypercholesterolaemia are cofactors which increase the risk of cardiovascular,
cerebrovascular and renal diseases, an investigative method which would recognise individuals at risk
would be a useful adjunct to their clinical management. Functional abnormalities are present in
established essential hypertension, and in hypercholesterolaemia. The non-invasive technique of drug
iontophoresis provides important new information about differences between dermal microvessels and
forearm resistance vessels. However, further investigation is required if this technique is to become






Hypertension and hypercholesterolaemia, along with diabetes mellitus, obesity,
smoking and left ventricular hypertrophy, are major risk factors associated with an
increased risk of atherosclerotic vascular disease. Alterations in the function and
structure of blood vessels, including impaired function of the vascular endothelium,
are present in both essential hypertension and hypercholesterolaemia. In hypertension,
functional abnormalities of blood vessels also include reduced capillary blood flow
under resting physiological conditions (Duprez et al, 1992), and after vasodilatation
produced by heating (Williams & Tooke, 1992). Structural abnormalities include
reduced luminal diameter in arterioles (Folkow, 1990; Heagerty et al, 1993) and in
capillaries (Lack et al, 1949; Landau & Davis, 1957; Harper et al, 1978). These
abnormalities cause an increase in peripheral vascular resistance which characterises
the disease, but it is unclear whether they are a cause or consequence of the rise in
pressure. This thesis investigates methods which detect mechanisms of endothelial
function in health, and of function and structure in hypertension and
hypercholesterolaemia. An understanding of such mechanisms may target more
appropriate intervention which would impede the complications of of these conditions.
1.2 VASCULAR FUNCTION
Functional abnormalities in essential hypertension may be explained by structural
defects, as has been observed in studies showing reduced blood flow in vessels
maximally dilated by physical stimuli such as heating (Williams et al, 1992). Blood
velocity in finger nailfold capillaries has been measured using the videomicroscopy
technique, and shown to be reduced (Duprez et al, 1992) or normal (Gasser & Biihler,
1992) in essential hypertension. Despite the findings of raised capillary pressures
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(Williams et al, 1990) and normal venous pressures (Widgren et al, 1992) in essential
hypertension suggesting that capillary or post-capillary vascular resistance is increased,
it remains uncertain whether changes in larger arterioles or whether changes in
capillaries are more relevant in human hypertension (Bohlen, 1989). Dysfuncton of the
blood vessels, affecting the vascular endothelium, has been attributed to impaired nitric
oxide generation, and has also been observed in hypertension (Calver et al, 1992;
Panza et al, 1990 &1993) and hypercholesterolaemia (Chowienczyk et al, 1992;
Casino et al, 1993).
1.2.1 Function of the vascular endothelium
The vascular endothelium forms the inner lining of all blood vessels, playing a major
role in the regulation of vascular function rather than acting simply as a barrier between
blood and vascular smooth muscle. It has become clear over the past 20 years that the
endothelium produces a number of important relaxing and contracting factors. In 1980,
Furchgott and Zawadski demonstrated that acetylcholine causes endothelium-
dependent vasodilatation of rabbit aortic rings, via the release of a labile humoral
factor, later known as endothelium-derived relaxing factor (EDRF) (Cherry et al,
1982). The humoral nature of EDRF was demonstrated in experiments in which it was
released by endothelium-intact rabbit aortic strips and shown to cause the relaxation of
adjacent endothelium-denuded vascular preparations (Furchgott, 1984; Griffith et al,
1984; Rubanyi et al, 1985). A variety of stimuli, such as adenine nucleotides,
bradykinin (BK), the calcium ionophore, A23187, substance P, thrombin, hypoxia,
increased flow, and electrical stimulation also induced endothelium-dependent
relaxation of vascular tissue in vitro, through the release of EDRF (Furchgott, 1983).
EDRF was shown to be released not only after stimulation by various agonists, but
also under basal conditions (Griffith et al, 1984; Rubanyi et al, 1985; Martin et al,
1985).
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The effects of EDRF on vascular smooth muscle and platelets are mediated through the
action of soluble guanylate cyclase, leading to an increase in cyclic guanosine
monophosphate (cGMP) (Ignarro et al, 1985; Rapoport et al, 1983; Waldman &
Murad, 1987). Vascular relaxation to EDRF was inhibited by haemoglobin and
methylene blue (Martin et al, 1985), and by dithiothreitol and hydroquinone (Griffith et
al, 1984). Furthermore, the effects of EDRF were prolonged by superoxide dismutase
(Gryglewski et al, 1986a; Rubanyi & Vanhoutte, 1986) and inhibited by Fe2+
(Gryglewski et al, 1986a). Superoxide anions were, therefore, suggested to contribute
to the instability of EDRF, not only because superoxide dismutase prolonged the
effects of EDRF, but also because inhibitors such as dithiothreitol, hydroquinone and
pyrogallol were shown to generate superoxide anions as a result of their redox
properties. In addition, cytochrome c, which removes superoxide anions, attenuated
the action of redox compounds, with pyrogallol (a generator of superoxide anions)
acting as an inhibitor of EDRF (Moncada et al, 1986).
Independently in 1986, Furchgott, and Ignarro and colleagues, suggested that EDRF
might be nitric oxide, since both EDRF and authentic nitric oxide (generated by
acidified nitrite; N02) activated guanylate cyclase, increased cGMP and caused smooth
muscle relaxation. Both EDRF and nitric oxide were inhibited by haemoglobin, and by
agents generating superoxide anions. Furthermore, the soluble guanylate cyclase
inhibitor, methylene blue, antagonised arterial relaxations to nitric oxide, whereas
inhibitors of cGMP-phosphodiesterase enhanced the response and caused an
accumulation of cGMP (Ignarro et al, 1988).
In 1987, Palmer, Ferrige and Moncada demonstrated that EDRF was nitric oxide.
Strips of endothelium-denuded rabbit aorta were perfused with effluent from porcine
aortic endothelial cells in culture. Stimulation of the cultured endothelial cells resulted
in release of EDRF and the relaxation of the bioassay tissues, a response that decayed
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with time during passage down the cascade, and which was inhibited by haemoglobin
and superoxide. When the generation of nitric oxide from cultured porcine vascular
endothelial cells was stimulated by bradykinin, levels were measured directly using a
chemiluminescent method. The resulting concentration-dependent release of nitric
oxide accounted for the vasodilatation of endothelium-denuded rabbit aortic strips
(Palmer et al, 1987), and the inhibition of platelet aggregation and adhesion (Radomski
et al, 1987).
The mechanism whereby nitric oxide stimulates guanylate cyclase is unclear, but it has
been proposed that nitric oxide reacts with the haem moiety, resulting in the formation
of a nitrosyl-haem complex (Ignarro et al, 1988). The generation of this complex alters
the configuration of the enzyme, converting it to its active form. The rise in cGMP then
leads to the activation of cGMP-dependent protein kinases and smooth muscle
relaxation by cytosolic calcium binding to calmodulin, resulting in the phosphorylation
of myosin light chains, relaxation of myosin cross-link bridges, and smooth muscle
cell relaxation (Rapoport et al, 1983).
Shikano and colleagues (1988) have questioned whether EDRF is nitric oxide,
demonstrating that nitric oxide, but not EDRF, relaxes non-vascular smooth muscle.
However, other workers have shown that both EDRF, released from cultured
endothelial cells or from rabbit aortic strips, and nitric oxide were equally effective in
relaxing non-vascular smooth muscle (Gillespie & Sheng, 1988; Angus & Cocks,
1989). Shikano and colleagues (1988) also suggested that EDRF, but not nitric oxide,
binds to anion exchange columns. In contrast, Furchgott and colleagues (1990)
demonstrated that anion exchange resins inhibit the relaxing activity of authentic nitric
oxide as well as EDRF from perfused rabbit aorta.
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Myers and colleagues (1990) suggested that EDRF more closely resembled
S-nitrocysteine (a nitrosothiol compound) which contains nitric oxide, than nitric oxide
itself, since the amount of nitric oxide released from cultured endothelial cells under
basal conditions or after stimulation by BK or the calcium ionophore A23187
(measured by the chemiluminescence method) was insufficient to account for the
relaxing activity of EDRF. It is possible that there were discrepancies in the
measurement of nitric oxide due to contamination with NO2, which often occurs
during preparation (Furchgott et al, 1990). The chemiluminescence method measures
both nitric oxide and N02, and may explain why, for biologically equipotent solutions
of EDRF and nitric oxide, the EDRF solution has been reported to have a lower
concentration of nitric oxide (Rubanyi et al, 1990). Rubanyi and colleagues (1990)
also found that, when equipotent solutions of EDRF and nitric oxide were passed
through a reduced haemoglobin column, only nitric oxide gave the typical nitrosohaem
electron paramagnetic resonance signal. However, N02 can also react with
haemoglobin to form paramagnetic nitrosyl-haemoglobin, thus giving the impression
that the concentration of nitric oxide is greater than is actually the case.
Nitrosothiols are, however, unstable in a neutral aqueous environment and decompose
rapidly, making it more likely that if EDRF was not nitric oxide, it would be a more
complex compound, such as a nitrosyl non-haem iron complex with thiol-containing
ligands (Vanin, 1991). Such complexes move within and between cells, and are
readily oxidised to produce nitric oxide and iron, accounting for their vasodilator and
platelet anti-aggregatory effects (Vanin, 1991).
In 1988, Palmer and colleagues demonstrated that L-arginine was the precursor for the
synthesis of nitric oxide by vascular endothelial cells, since endothelial cells cultured in
the absence of L-arginine for 24 h showed a decrease in the release of EDRF induced
by bradykinin and A23187, an effect which could be restored by L- but not D-arginine
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(Palmer et al, 1988). These findings also suggested the involvement of an enzyme
(nitric oxide synthase) in the formation of nitric oxide. Using mass spectrometry, nitric
oxide was shown to be formed from the terminal guanidino nitrogen atom(s) of
L-arginine when cells were stimulated with bradykinin. N®Hydroxy-L-arginine is
generated as an intermediate in the biosynthesis of nitric oxide and is coupled to the
oxidation of 1 mol of nicotinamide adenine dinucleotide phosphate (NADP; or the
reduced form: NADPH) by nitric oxide synthase (NOS). A further reaction converts
the intermediate into nitric oxide and citrulline, in conjunction with the oxidation of 0.5
mol ofNADPH and tetrahydrobiopterin (Fig. 1.1; Marietta, 1989; Stuehr et al, 1991).
The biosynthesis of nitric oxide from L-arginine by NOS results in the formation of
citrulline as a coproduct (Palmer et al, 1989) and the incorporation of molecular
oxygen into both nitric oxide and citrulline (Leone et al, 1991).
H








H,N2.m cooh h2n- 'COOH H2N"' "-COO"
L-arginine NG-hydroxy-L-arginine nitric oxide L-citrulIine
(Marietta, 1989)
FIGURE 1.1:
Biosynthesis of nitric oxide and L-citrulIine from L-arginine via the intermediate NC0hydroxy-L-arginine.
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1.2.2 Nitric oxide synthases
The L-arginine:nitric oxide pathway was, thus, established and two differentially
regulated NOS isoforms were classified. Constitutive NOS was found to be
calcium/calmodulin-dependent (Biisse & Miilsch, 1990; Mayer et al, 1990), and
inducible NOS calcium/calmodulin-independent (Hauschildt et al, 1990), with both
isoforms being NADPH- and tetrahydrobiopterin-dependent (Marietta et al, 1988;
Kwon et al, 1989; Palmer & Moncada, 1989). However, the recent identification of a
calmodulin binding sequence in mouse macrophage-inducible NOS (Cho et al, 1992),
which tighdy binds calmodulin, questioned the validity of this classification, and
suggested that there might be three isoforms of NOS: two constitutive enzymes (one
expressed in endothelium, the other in brain) and an inducible enzyme synthesised in
macrophages.
This classification has been further updated, and NOS enzymes (now termed
inducible, constitutive and neuronal) have been isolated from a range of tissues and
species. Neuronal nitric oxide synthase (nNOS) generates nitric oxide which is a
neurotransmitter and neuromodulator, released from non-adrenergic, non-cholinergic
(NANC) nerves, and may be involved in nociception, penile erection and bladder
sphincter control (Knowles & Moncada, 1994). Activation of constitutive nitric oxide
synthase (cNOS) is calcium/calmodulin-dependent. Endothelial cNOS is sometimes
referred to as eNOS. Activation of mouse macrophage NOS is not controlled by
changes in intracellular calcium, since this form binds calmodulin tightly at basal
intracellular levels of calcium (Cho, 1992). Induction of new protein is required to
synthesise this NOS, hence it is called inducible (iNOS) (Xie et al, 1992). Recently,
inducible NOS isolated from macrophages was shown to contain a haemoprotein
which is directly involved in the oxidative conversion of L-arginine to nitric oxide and
citrulline (White & Marietta, 1992).
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In addition to its role in regulating vascular tone, nitric oxide inhibits platelet
aggregation and adhesion (Radomski et al, 1987), and has a role in peripheral and
central neurotransmission (Gillespie et al, 1989; Knowles et al, 1989).
Immunohistochemical studies have localised the constitutive NOS in discrete neuronal
populations within the brain (where nitric oxide mediates the actions of the excitory
neurotransmitter, glutamate) and in cell bodies and nerve fibres in the mesenteric
plexus of the intestine (where nitric oxide, released after neuronal stimulation, leads to
relaxation of the intestine) (Bredt et al, 1990 & 1991). The synthesis of nitric oxide by
this enzyme is rapid, short-lasting and not dependent on exogenous L-arginine.
Nitric oxide released from inducible NOS in macrophages contributes to their
cytotoxic/cytotactic actions against tumour cells, bacteria and protozoa (Hibbs et al,
1990), whereas nitric oxide released after immunological stimulation of vascular
endothelial cells contributes to pathological vasodilatation (Kilbourne et al, 1990; Rees
et al, 1990a; Thiemermann & Vane, 1990) and tissue damage (Hutcheson et al, 1990;
Palmer et al, 1992).
Following recent advances in molecular biology, the three isoforms of NOS have been
cloned and sequenced: the constitutive enzyme from the rat (Bredt et al 1991) and
bovine (Lamas et al, 1992) cerebellum, and rat (Sessa et al, 1992), bovine (Lamas et
al, 1992) and human (Marsden et al, 1992) endothelium; and the inducible enzyme
from the mouse macrophage (Xie et al, 1992). The three NOS isoforms show little
sequence homology. The constitutive enzymes show only 60% homology (Lamas et
al, 1992; Marsden et al, 1992) and are encoded by distinct genes (Lamas et al, 1992).
The inducible isoform shows only 50-60% homology with the constitutive enzymes
(Lamas et al, 1992; Sessa et al, 1992; Xie et al, 1992).
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1.2.3 Nitric oxide in the regulation of vascular tone
In vitro
The release of nitric oxide from endothelial cells in culture (Palmer et al, 1988), the
synthesis of citrulline by endothelial cell homogenates (Palmer & Moncada, 1989), and
the endothelium-dependent relaxation induced by acetylcholine (Palmer et al, 1988) are
inhibited by the L-arginine analogue and NOS inhibitor, L-iVG-monomethyl-arginine
(L-NMMA). This inhibitor causes a significant endothelium-dependent contraction of
rabbit and rat aortic rings (Palmer et al, 1988; Rees et al, 1990a). Both of these effects
are reversible by L-, but not by D-arginine (Rees et al, 1989). These studies indicated
that there is a continuous basal release of nitric oxide which is involved in maintenance
of blood vessel tone, and that acetylcholine stimulates the synthesis of nitric oxide
from L-arginine resulting in vasodilatation (Palmer et al, 1988).
There is evidence suggesting that basal and stimulated release of nitric oxide may be
differentially modulated by changes in the concentration of extracellular calcium
(Lopez-Jaramillo et al, 1990). Although, in the vascular endothelium, both
mechanisms of nitric oxide release are calcium/calmodulin-dependent (Biisse &
Miilsch, 1990), the release of nitric oxide by acetylcholine occurs over a wider range
of calcium concentrations (0.5-2.0 mM), compared with those at which basal release
occurs (0.75-1.50 mM) (Lopez-Jaramillo et al, 1990). There are several possible
explanations for the differential requirements for calcium. First, there may be two
different mechanisms by which calcium enters the cell to stimulate the synthesis of
nitric oxide. For example, basal release may occur as a consequence of the opening of
stretch-activated calcium channels by pulsatile flow (shear stress), with release by
acetylcholine occurring through receptor-mediated calcium channels. Second,
acetylcholine may utilise a greater amount of intracellular calcium.
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In vivo
L-VG-monomethyl-arginine causes a significant rise in blood pressure in anaesthetised
rabbits (Rees et al, 1989), rats (Whittle et al, 1989; Tolins & Raij, 1990), and guinea
pigs (Aisaka et al, 1989). This rise in pressure, accompanied by a decrease in renal,
mesenteric, carotid and hindquarter vascular conductances in the conscious rat
(Gardiner et al, 1990a), suggests a widespread role for nitric oxide in maintaining
vascular tone throughout the cardiovascular system. This is supported further by the
work of Vallance and colleagues (1989) in which brachial artery infusion of L-NMMA
causes vasoconstriction, indicating that basal generation of nitric oxide maintains
vascular tone by opposing vasoconstrictor mechanisms.
In anaesthetised rats, acetylcholine causes a fall in mean arterial blood pressure (Rees
et al, 1990b) which is accompanied, in the conscious animal, by a hyperaemic
vasodilatation in the renal vascular bed (Gardiner et al, 1990b). The hypotensive
response to acetylcholine in anaesthetised rats is either partly (Rees et al, 1990b) or
almost completely (Whittle et al, 1989) inhibited by L-NMMA. In man, the
vasodilatation to acetylcholine in the dorsal hand vein and brachial artery is also partly
inhibited by L-NMMA (Collier & Vallance, 1989; Vallance et al, 1989a & 1989b). The
reason for the incomplete inhibition of the acetylcholine response is not clear, although
a clue comes from work by Aisaka and colleagues (1989) in which they were unable to
inhibit the acetylcholine-induced fall in blood pressure in anaesthetised guinea pigs, but
were able to reduce the duration of hypotension. They suggested that the acetylcholine
depressor response may have two phases, an initial phase in which the fall in blood
pressure does not require increased synthesis of nitric oxide, and a succeeding phase in
which longer-lasting dilatation can be inhibited by L-arginine analogues.
Invasive, intra-arterial infusion studies have shown that, in the forearm, cholinergic
dilatation is mediated principally by nitric oxide, since the response is inhibited by the
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nitric oxide synthase inhibitor, L-NMMA (Vallance et al, 1989), and reversed by
L-arginine (Panza et al, 1993a). However, the relative contribution of the mediators of
endothelium-dependent vasodilation varies between tissues. Thus, in renal arteries,
prostacyclin is the principal mediator, accounting for the constrictor effect of
cyclooxygenase inhibitors in this vascular bed (Breierwates et al, 1982; Ito et al,
1989). Vasodilatation by acetylcholine could also be due to presynaptic inhibition of
noradrenaline release, but this is unlikely because the response is not affected by the
non-selective a-blocker, phentolamine (Panza et al, 1990; Linder et al, 1990).
Furthermore, vasodilatation is not inhibited by the cyclooxygenase inhibitor, aspirin
(Linder et al, 1990). Another possibility is that the inhibition of acetylcholine-induced
vasodilatation by L-arginine analogues is reduced under conditions of highly effective
receptor-coupling (Giles et al, 1990), suggesting that the lack of inhibition by these
analogues is not necessarily evidence for the lack of involvement of nitric oxide in
endothelium-dependent relaxation responses. In addition, muscarinic receptor subtypes
initiating vascular relaxation to acetylcholine in vitro are complex (Rubanyi et al,
1986c), and differential inhibition of different agonists by L-NMMA could result from
actions on receptor subtypes linked with more than one effector mechanism, not all of
which involve the L-arginine:nitric oxide pathway (Chowienczyk et al, 1993).
Furthermore, vascular relaxations may be mediated through an endothelium-derived
hyperpolarising factor (EDHF) (Feletou & Vanhoutte, 1988).
1.2.4 Inhibitors of nitric oxide synthesis
With the advent of other L-arginine analogues as inhibitors of NOS (e.g.,
L-A^-nitro-arginine methyl ester (L-NAME) and L-N-iminoethyl-ornithine (L-NIO)),
there is growing evidence suggesting that basal and stimulated NOS may be
differentially regulated. This may explain the findings of Lopez-Jaramillo and
colleagues (1990; see earlier) that changes in the concentration of extracellular calcium
have a fundamental effect on stimulated and basal release of nitric oxide. The three
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analogues, L-NMMA, L-NAME and L-NIO, have different potencies in inhibiting basal
and stimulated nitric oxide synthesis in isolated rings of rat aorta, and in anaesthetised
rats (Rees et al, 1990b), as well as in isolated perfused rabbit hearts (Smith et al,
1992). These inhibitors of NOS are discussed in the next chapter (Chapter 2), where
the rationale is given for using L-NMMA as the inhibitor of choice throughout the
studies described in this thesis.
Arachidonic acid, or one of its metabolites, may have a role in the differential
regulation of basal and stimulated nitric oxide synthesis (Crack & Cocks, 1992).
Thimerosal (an inhibitor of acetyl-CoA acetyltransferase) fully relaxed
endothelium-intact rings of canine coronary artery. However, after the response to
thimerosal had faded, these tissues no longer responded to acetylcholine, bradykinin or
substance P, although they did respond to the nitric oxide donor, sodium
nitroprusside. Endothelium-dependent contractions to L-NMMA and L-NAME were
unaffected. Furthermore, L-NMMA and L-NAME blocked the relaxation to thimerosal.
Since thimerosal induces the mobilisation of arachidonic acid, these authors suggested
that arachidonic acid, or one of its non-cyclooxygenase metabolites, may play a role in
the regulation of stimulated nitric oxide synthase, and that basal and stimulated release
may be differentially regulated.
1.2.5 Vasoactive prostanoids
The endothelium produces other vasodilators, including prostacyclin (Moncada et al,
1991) and the putative hyperpolarising factor (Feletou & Vanhoutte, 1988; Kilpatrick
& Cocks, 1994; Garland et al, 1995) (Figure 1.2). Stimulated endothelial cells (and
circulating platelets) release free arachidonic acid from their membrane phospholipid
pools and rapidly oxidise it to form the labile prostaglandin (PG) endoperoxides PGG2
and PGH2, via the cyclooxygenase enzyme which can be inhibited by aspirin (Flower,
1974; Schafer et al, 1984; Barrow et al, 1988). Platelets also oxidise arachidonic acid
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to form hydroperoxy- and hydroxy-fatty acids via the lipoxygenase pathway which is
not blocked by aspirin. The endoperoxides of endothelial cells and platelets serve as
substrates for the enzymatic formation of two labile eicosanoids of potent but opposing
biological effects, prostacyclin (PGI2) and thromboxane A2 (TXA2). Endothelial PGI2
synthase converts PGH2 to PGI2, which increases levels of cAMP in vascular smooth
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Schematic diagram of acetylcholine stimulating an endothelial cell to generate nitric oxide (NO)
through the action of nitric oxide synthase (NOS), and prostacyclin (PGI2) through the action of
prostacyclin synthase (PS), to cause relaxation of vascular smooth muscle by increasing cGMP and




Inhibition of endothelial generation of relaxing factors by the nitric oxide synthase inhibitor,
L-A^-monomethyl-arginine (L-NMMA) and the cyclooxygenase inhibitor, aspirin. Nitric oxide can be
donated directly to the smooth muscle by nitrovasodilators such as sodium nitroprusside. Exogenous
prostacyclin can also be donated. (Abbreviations as Fig. 1.2.)
Prostanoids may act synergistically with nitric oxide in some preparations, since
vasodilator prostanoids augment endothelium-dependent relaxations (Shimokawa et al,
1988). However, inhibition of prostanoid generation by indomethacin does not
influence the synthesis or action of nitric oxide released by endothelial cells
(Gryglewski et al, 1986b), or the relaxation of rabbit mesenteric artery strips and
arterioles of the hamster cheek pouch (Moncada et al, 1988; Rees et al, 1990c). Since
prostacyclin and nitric oxide exert anti-atherosclerotic and anti-thrombotic effects (Vane
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& Botting, 1994), these may have important implications in pathological conditions
such as atherosclerosis.
Prostacyclin is a powerful inhibitor of the release of mitogens from platelets,
endothelial cells and macrophages (Willis et al, 1987) and, thus, when formed by
endothelial cells will suppress smooth muscle proliferation in atherosclerotic plaques.
Prostacyclin inhibits accumulation of cholesterol in macrophages (Willis et al, 1986)
and in vascular smooth muscle cells (Hajjar, 1985), and should, therefore, suppress
the formation of foam cells which are involved in the early stages of atherosclerotic
plaque formation (Chapter 5). This last effect is reinforced by the actions of
prostaglandin (PGE2), and high density lipoprotein (HDL). PGE2 inhibits
acetyl-CoA/cholesterol O-acetyltransferase (see above), and prostacyclin (PGI2)
stimulates acid cholesteryl ester hydrolase, whereas HDL serves as a cholesterol carrier
(Hajjar, 1985). It may be, therefore, that the PGI2 and PGE2 generating system is
responsible for clearing cholesteryl esters from the vascular wall, whereas inhibition of
cyclooxygenase or prostacyclin synthase by lipid hydroperoxides (Lands, 1985)
brings about an accumulation of cholesteryl esters in the vascular wall, formation of
foam cells and atherogenesis.
This may be the major role for prostacyclin generated by endothelial cells. Blood
pressure is not altered by administration of aspirin or indomethacin (Vane & Botting,
1994) which prevent both vasodilator and vasoconstrictor prostanoid production, thus,
it is unlikely that prostacyclin is contributing to the maintenance of blood vessel tone in
health. The role of prostacyclin in atherosclerotic vascular disease is discussed further
in Chapter 5.
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1.2.6 Constricting factors produced by the endothelium
The endothelium also produces vasoconstrictors, such as angiotensin II (Webb &
Cockcroft, 1990) and endothelin-1 (ET-1). ET-1 is a21-amino acid peptide isolated
by Yanagisawa and colleagues (1988) from porcine aortic endothelial cells, and the
most potent endogenous vasoconstrictor yet identified. ET-1 is the predominant
peptide, but two other isoforms, ET-2 and ET-3, have also been isolated. ET-1 binds
to at least two distinct receptor subtypes: ETa which appears to be the major receptor
mediating vasoconstriction in arteries; and ETb which mediates release of endothelium-
dependent vasodilating factors and is also present in some resistance and capacitance
vessels where it contributes to vasoconstriction. ET-1 contributes to the maintenance of
basal vascular tone (Haynes & Webb, 1994), which may be altered in diseases such as
hypertension, heart failure, renal failure and Raynaud's disease (Haynes & Webb,
1993). There may be a balance, therefore, between endothelium-derived relaxing and
contracting factors which is perturbed in some diseases. The role of the endothelins is
not addressed in this thesis.
1.2.7 Dysfunction of the vascular endothelium
In the forearm of hypertensive humans, basal nitric oxide production is reduced since
L-NMMA causes diminished vasoconstriction (Calver et al, 1992: Panza et al, 1993a)
suggesting reduced basal nitric oxide production. Cholinergic dilatation and
vasodilatation to an alternative stimulus to nitric oxide synthesis (substance P) may
also be impaired (Panza et al, 1994). Both L-NMMA and L-arginine have no effect on
cholinergic dilatation (Panza et al, 1993a and 1993b). In addition, some studies have
shown that patients with essential hypertension also have impaired vasodilatation in
coronary vessels following intracoronary infusion of acetylcholine (Treasure et al,
1993), and impaired cholinergic dilatation in excised gluteal resistance vessels (Falloon
et al, 1992). In contrast, the findings of Cockcroft et al, (1994) suggest that
impairment in stimulated vasodilatation in the forearm vasculature is not universal in
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patients with essential hypertension. It may be that endothelial dysfunction causes
selective impairment to acetylcholine in a subgroup of hypertensive patients, not
represented in the latter study.
Indomethacin normalises impaired cholinergic dilatation in the forearm bed of
hypertensive patients (Taddei et al, 1993). This normalisation of the acetylcholine
response following cyclooxygenase inhibition has also been seen in spontaneously
hypertensive rats (Iwama et al, 1992), and in stroke-prone spontaneously hypertensive
rats (Diederich et al, 1990), suggesting that the release of relaxing factors is normal,
but that the concomitant, possibly enhanced, release of a cyclooxygenase-dependent
endothelium-derived contracting factor (probably prostaglandin H2) (Taddei et al,
1993) accounts for the impaired relaxation. Further, defects in the metabolism of the
contracting prostanoid, PGH2 could cause an upregulation of its synthesis, which
could inhibit prostacyclin synthase (Lin, 1994).
Patients with hypercholesterolaemia also have impaired basal (Casino et al, 1993) and
stimulated (Chowienczyk et al, 1992; Casino et al, 1993) release of nitric oxide in the
forearm vascular bed, and in the coronary circulation (Drexler & Zeiher, 1991).
Hypercholesterolaemia leads to atherosclerosis, a process which is accelerated if
hypertension is present. Thus, the capacity of the endothelium to maintain adequate
tone and to prevent thrombus formation in hypercholesterolaemic patients may have
important implications for atherogenesis. This is discussed in detail in Chapter 5.
It is unclear whether impaired nitric oxide generation in hypertension and
hypercholesterolaemia is confined to skeletal muscle resistance vessels and coronary
vessels, and whether the defect is specific to nitric oxide generation or whether, in
humans, the impaired function also affects other mediators such as prostacyclin (see
Chapter 5). Moreover, it seems that caution should be taken in assessing endothelial
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dysfunction using the acetylcholine test, as some patients with hypertension
(previously treated or untreated) have no difference in cholinergic vasodilatation in the
forearm compared with normotensive controls (Cockcroft et al, 1994). Alternatively,
the invasive methodology of forearm perfusion studies has not allowed sufficient
numbers of patients to be examined to establish the epidemiology of endothelial
dysfunction.
Central to this thesis, therefore, is the development of a simple, non-invasive technique
for investigating endothelial function both in health and in diseases such as essential
hypertension and hyperlipidaemia. The technique of transdermal delivery of drugs by
iontophoresis combined with laser Doppler monitoring of blood flow (Chapters 4-6),
will be used, not only to assess function, but also to explain the underlying
pharmacological mechanisms of cholinergic vasodilatation in dermal microvessels.
1.3 VASCULAR STRUCTURE
1.3.1 Hypertrophy
In addition to functional abnormalities, defects in the structure of blood vessels may
also explain abnormalities in hypertension. Resistance to blood flow can be altered by
structural abnormalities of the vasculature, and in a single, straight blood vessel,
resistance can be approximated using Poiseuille's equation, R = Slh/rcr4, where R =
resistance, l=the length of the vessel, h = blood viscosity, and r = the vessel radius,
i.e.,




Total resistance in a tissue, however, is influenced by many other structural, functional
and theological factors. The luminal sizes of resistance arteries brought to a state of
complete relaxation are determined by their structural characteristics and distending
pressure. In hypertensive patients, blood flow is reduced in vessels which are
maximally dilated, thus, minimum resistance to flow is increased (Folkow et al, 1958
and 1990; Pedrinelli et al, 1990). These investigators induced maximum dilatation in
forearm blood vessels in humans using physical or pharmacological means, and
measured resulting blood flow plethysmographically, thus, providing a haemodynamic
index for quantifying arteriolar structural changes in hypertension. To account for this
combination of reduced flow and higher resistance, Folkow (1958) postulated the
presence of structural abnormalities including a reduction in blood vessel luminal size
together with an increase in wall thickness (i.e., increased vessel wall:lumen ratio).
This theory for structural abnormalities has been the predominant explanation since
Folkow's initial experiments. However, it may be possible that the increase in
resistance could be due to a reduced number of vessels (rarefaction; see below), rather
than increased walklumen ratio, and this will be investigated in Chapter 6.
It was previously thought that the increase in walklumen ratio was the result of growth
of the media into the vessel lumen. Recently, however, Heagerty and colleagues
(1993) have reported that, in patients with essential hypertension, myocyte number is
normal, with no increase in growth rate. This may be explained by the 'remodelling'
theory, i.e., a process of medial cells rearranged around a narrowed lumen (Baumbach











Schematic, annotated drawing showing different modes of structural change of arteries. The lower
artery shows remodelling as described by Baumbach & Heistad (1989), with consequent reduction in
luminal diameter.
With sustained hypertension, vascular hypertrophy is correlated with left ventricular
hypertrophy (Casale et al, 1986; Agabiti-Rosei et al, 1988 & 1991). Paradoxically, left
ventricular hypertrophy correlates poorly with mean arterial pressure (Tarazi et al,
1982; Hartford et al, 1983) and is sometimes present before pressure starts to rise
(Tarazi, 1985). Alternative mechanisms contributing to left ventricular hypertrophy
include increased cardiac sympathetic nerve stimulation and the trophic effects of
circulating catecholamines and angiotensin II (Hartford et al, 1983). Therefore,
sympathetic nerves and circulating mediators may regulate growth and contraction of
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the heart muscle (Simson, 1985) causing ventricular hypertrophy, as well as of blood
vessel smooth muscle (Hart et al, 1980; Folkow, 1983) causing vascular hypertrophy.
Blood vessel compliance is also reduced in hypertension (Safar et al, 1992), and could
be due either to structural changes in smooth muscle layer thickness or to alterations in
function. If smooth muscle thickening causes encroachment into the lumen and the
walls are distensible, it may be possible to compensate for reduced luminal diameter by
increased stretching. However, in the common carotid artery of the anaesthetised rat in
vivo, Levy and colleagues (1988 and 1990) observed that for any given pressure,
luminal volume was significantly reduced in hypertensive rats indicating stiffer arterial
walls. Following the application of potassium cyanide to poison the arterial smooth
muscle, compliance increased significantly both in hypertensive and in normotensive
rats, indicating the influence of vasomotor tone. However, compliance remained
substantially lower in hypertensive rats, suggesting that structural factors were
predominant in maintaining compliance.
As the microcirculation is area of the cardiovascular system making the greatest
contribution to peripheral vascular resistance, alterations in microvascular structure and
function effect such resistance. However, these alterations may or may not occur
predominately in the microcirculation. Moreover, vessels affected by atherosclerosis
are larger, and are important by their contribution to myocardial infarction and stroke.
Microvessels with a luminal diameter of less than 150 pm have been classed as true
resistance vessels (Prewitt & Wang, 1991; Struijker Boudier et al, 1992). However, it
is often unclear from the literature whether or not reference to 'resistance vessels'
includes these small microvessels. Schiffrin (1992) divides the arterial side of the
circulation into two groups of vessels, depending on their internal (luminal) diameter,
i.e., large blood vessels (>300 pm i.d.) and small blood vessels (<300 pm i.d.). The
greatest resistance to flow occurs in the group of vessels with an internal diameter of
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less than 300 Jim, including the arterioles (<150 (im i.d.) which dominate the control
of blood flow (Prewitt & Wang, 1991; Struijker Boudier et al, 1992). Peripheral
vascular resistance, therefore, is dictated primarily by true resistance vessels of luminal
diameter less than 150 (im. In essential hypertension, the characteristic increase in
peripheral vascular resistance is therefore most likely to reflect structural or functional
changes (see above) in these microvessels (Shore & Tooke, 1994).
The hypertrophy of cerebral vessels from stroke-prone spontaneously hypertensive
rats is attenuated in vessels which have undergone sympathetic denervation (Hart et al,
1980). However, mechanisms other than sympathetic innervation also exert trophic
effects on the vascular smooth muscle causing structural and functional changes. For
example, catecholamines stimulate growth of vascular smooth muscle in culture (Blaes
& Boissel, 1983) causing structural change, and hypertensive humans exposed to
noradrenaline or serotonin show the functional abnormality of increased vascular
reactivity (a greater force per unit area of muscle) compared with control subjects
(Schiffrin, 1992). Evidence from humans (Campbell-Boswell & Robertson, 1981) and
animals (Schelling et al, 1979) suggests that angiotensin n also has a trophic or
mitogenic action on smooth muscle, and augments sympathetically-mediated arteriolar
constriction in man (Seidelin et al, 1991). The effect of vasoconstrictors, therefore,
appears to be amplified in hypertension, and other mediators, such as those produced
by the vascular endothelium may also be involved in altering structure and function of
blood vessels in this disease.
1.3.2 Rarefaction
As well as a reduction in luminal cross-sectional diameter, a reduction in the density of
vessels per volume of tissue (rarefaction) will increase vascular resistance. Rarefaction
may be functional when the tissues are temporarily not perfused or 'recruited', or
structural, when the absolute number of vessels is reduced. Several studies have
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confirmed capillary rarefaction in some but not all tissues from hypertensive animals
(Hutchins & Darnell, 1974; Chen et al, 1981; Vicaut, 1992). In essential hypertension,
structural differences in conjunctival capillaries were observed as long ago as the
1920s (Boas & Frant, 1922; Boas & Mufson, 1923), and more recently rarefaction has
been demonstrated using conjunctival microphotography (Lack et al, 1949; Harper et
al, 1978; Sullivan et al, 1983), and videomicroscopy of dermal vessels (Williams et al,
1986; Gasser & Biihler, 1992), when it was associated with luminal narrowing of
capillaries.
1.4 HYPERTENSION AND ATHEROSCLEROSIS
Hypertension accelerates the atherosclerotic process (Ross et al, 1986) which is of
particular importance in coronary arteries (Chobanian et al, 1989). Structural and
functional alterations of blood vessels are not confined to hypertension, but may also
play an important role in the pathophysiology of the complications of
hypercholesterolaemia (Vanhoutte, 1991; Rabbani & Loscalza, 1991). Several
experimental and clinical studies have shown that hypercholesterolaemia is associated
with accelerated atherogenesis (Ross et al, 1986). However, before developing any
anatomical evidence of atherosclerotic lesions, dysfunction of the endothelium may be
present (Simionescu et al, 1990), particularly impaired endothelium-dependent
relaxation (Shimokawa et al, 1989). High cholesterol, particularly low density
lipoprotein (LDL) cholesterol, levels seem to impair the regulatory function of the
endothelium long before the development of fatty streaks (Badimon et al, 1992). Thus,
the potential for a non-invasive method of screening for dysfunction early in the
development of the disease, would help in clinical management and prevention of
complications, and this is the subject of Chapter 5.
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1.5 FUNCTIONAL AND STRUCTURAL ABNORMALITIES: CAUSE
OR CONSEQUENCE?
From studies in established hypertension it is not possible to ascertain whether
vascular abnormalities are a cause or consequence of the rise in blood pressure.
Circumstantial evidence suggests that they are causal, since they occur early in the
development of hypertension (Sullivan et al, 1983; Lever & Harrap, 1992) and are not
closely correlated with other consequences of hypertension such as increased left
ventricular mass (Lucarini et al, 1991).
1.5.1 Blood pressure tracking
Blood pressure increases with age in children at all ages (Johnson et al, 1973; Katz et
al, 1980; Hait et al, 1982), but is especially pronounced during the first year of life, a
period of rapid growth (Tanner et al, 1966). Individuals maintain a consistent position
over several years when ranked in terms of blood pressure (Rosner et al, 1977). Lever
& Harrap (1992), therefore, propose a genetically determined imbalance in the
endocrinological growth-promoting processes in children who become hypertensive.
During maturation and ageing in adulthood, the rates of change in physiological and
biochemical processes are different in essential hypertensive patients compared with
normal adults, indicating a disordered biological clock in these patients (Birkenhager,
1972; Brown, 1983).
Hence, alterations in the vasculature may have their origins in childhood, and may
contribute to the aetiology of essential hypertension. Therefore, I have used a novel
epidemiological model, the Ladywell 'four comers' model, to study causal




Functional abnormalities of microvessels observed in essential hypertension include
reduced capillary blood flow both in the basal state (Duprez et al, 1992) and after
vasodilatation induced by heating (Rayman et al, 1986; Williams et al, 1992). Using
invasive procedures, functional abnormalities of the vascular endothelium have been
observed in essential hypertension (Panza et al, 1990; Calver at al, 1992; Taddei et al,
1993) and also in hypercholesterolaemia (Chowienczyk et al, 1992; Casino et al,
1993). This 'endothelial dysfunction' has been attributed to impaired generation of
nitric oxide.
Structural abnormalities in microvessels of hypertensive patients include: decreased
luminal diameter occurring predominantly in larger arterioles (Folkow, 1990; Heagerty
et al, 1993), and in capillaries (Lack et al, 1949; Landau & Davis, 1957; Harper et al,
1978); and a reduction in the density of vessels per volume of tissue (rarefaction)
occurring predominantly in the smallest vessels (Lack et al, 1949; Landau & Davis,
1957; Harper et al, 1978; Sullivan et al, 1983; Henrich et al, 1988; Williams et al,
1986,1990; Gasser & Biihler 1992; Prasad et al, 1995).
In human essential hypertension, it is unclear whether structural changes in capillaries
or whether changes in larger arterioles are more relevant (Bohlen, 1989).
Micropuncture studies show that capillary pressures are elevated in essential
hypertension (Williams et al, 1990) while venous pressure is normal (Widgren et al,
1992), suggesting that capillary or post-capillary vascular resistance is increased.
Therefore, microvessels are significantly involved in the pathophysiology of essential
hypertension (Shore & Tooke, 1994).
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1.7 AIMS
The aims of this thesis are:
♦ To examine the role of nitric oxide in the maintenance of basal vascular tone in
health, and to investigate the importance of nitric oxide in the control of blood
pressure and cardiovascular homeostasis (Chapter 2).
♦ To extend this investigation of nitric oxide to the skin microcirculation,
examining its role in the control of microvascular blood flow in nutritive and
arteriovenous anastomotic tissues of the hand skin (Chapter 3).
♦ To validate the non-invasive technique of transdermal delivery of drugs by
iontophoresis combined with laser Doppler fluximetry (Chapter 4).
♦ To investigate the pharmacological mechanisms of cholinergic vasodilatation in
dermal microvessels, using this iontophoresis technique, and to assess whether
the cholinergic response is mediated by nitric oxide and/or prostacyclin
(Chapter 4).
♦ To assess the ability of iontophoresis to measure endothelial function in
hypercholesterolaemic patients (Chapters 5).
♦ To use the Ladywell 4 corners epidemiological model to study vascular
structure and function in young people with contrasting predisposition to high
blood pressure (Chapter 6).
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Chapter 2
NITRIC OXIDE CONTRIBUTES TO BLOOD
PRESSURE CONTROL IN MAN
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2.1 INTRODUCTION
Nitric oxide is a short-lived free radical molecule with potent vasodilatory and anti¬
aggregatory effects (Palmer et al, 1987). It is generated by the vascular endothelium,
through the action of the nitric oxide synthase enzyme on its substrate, the amino acid
L-arginine (Moncada et al, 1991). Analogues of L-arginine, such as
L-AG-monomethyl-arginine (l-NMMA), and l-V®-nitro -arginine methyl ester
(L-NAME) which circulate at low concentrations in blood (Vallance et al, 1992), are
competitive inhibitors of nitric oxide synthase (Moncada et al, 1991). l-NMMA was
used as the inhibitor of choice throughout the studies described in this thesis, because,
firstly, it is a specific inhibitor of nitric oxide synthase (Moncada et al, 1990) without
effects at muscarinic receptors (Buxton et al, 1993); secondly, it has been used in
humans extensively (Vallance et al 1989; Calver et al, 1992a; Drexler et al, 1992;
Chowienczyk et al, 1993; Panza et al, 1993b; Stamler et al, 1994). l-NAME was not
used because it is an antagonist at muscarinic receptors (Buxton et al, 1993), and, by
acting at histamine (H2) receptors on vascular smooth muscle cells, l-NAME may
block vascular relaxation independently of the endothelium (Kristic et al, 1991; Ortiz et
al, 1992). By blocking generation of nitric oxide, l-NMMA constricts isolated blood
vessels in vitro and is a pressor agent in vivo in animals (Moncada et al, 1991).
In healthy human subjects, in vivo evidence has previously been limited to brachial
artery administration of l-NMMA, which causes around a maximum 50% reduction in
forearm blood flow, suggesting that basal generation of nitric oxide may oppose
vasoconstrictor mechanisms in forearm vessels (Vallance et al, 1989). The experiments
described in this chapter provide evidence that nitric oxide generation influences blood
pressure in healthy humans. The effects of systemic inhibition of nitric oxide synthesis





Eight healthy male subjects (age range: 22-60 yr) gave written informed consent to this
randomised, single-blind, two-phase crossover study, which was approved by the
Lothian Ethics of Medical Research Committee. No subject received vasoactive or non¬
steroidal anti-inflammatory drugs during the week before each phase of the study, and
all of the subjects abstained from alcohol for 24 hours, and from food, caffeine-
containing drinks and cigarettes for at least 2 h before each phase. Subjects rested in
the recumbent position during each phase, in a quiet room maintained at a constant
temperature of 22-25°C. Intravenous cannulae were placed in the left and right
antecubital veins under local anaesthesia (left for infusion; right for blood sampling).
2.2.2 EXPERIMENTAL PROTOCOL
(i) DOSE-RANGING PILOT STUDIES
There was an initial series of pilot dose-ranging studies in which two subjects
received, on separate days, doses of L-NMMA in ascending order (0.03, 0.1, 0.3, 1.0
and 3.0 mg kg"1) infused at 1 ml mim1 over 60 min. On a separate occasion, each
subject received saline placebo, with the order of the infusions randomised. Further
pilot studies were performed in five of the subjects, in whom 3.0 mg kg-1 l-NMMA
was infused over 20 min. Further to the results of these pilot studies (Table 2.1), we
examined the effects of 3 mg kg"1 L-NMMA administered over 5 min to eight subjects
in a single-blind, placebo-controlled crossover study.
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Change in blood pressure (mmHg) A heart rate A cardiac index A TPRI
Dose
(mg kg"1) n
Systolic Diastolic Mean (beats min'1) (lmin1 m'2) (dyn min cm"5 m"2)
Placebo 9 1218.1 2.9110.5 2418.3 1.8111.1 0.0310.53 0.014.1
L-NMMA
0.03 (over 60 min) 2 4.5142 2513.5 3.210.9 11.010.0 0.1010.42 2.312.2
0.1 (over 60 min) 2 13.312.5 0.515.7 4.814.6 10.612.2 -0.2010.14 2512.3
0.3 (over 60 min) 2 2.5119.8 6.3116.6 5.0117.7 12018.5 0.2510.21 1.715.3
1.0 (over 60 min) 2 1.5114.1 -0.813.9 0.013.9 -10.812.5 -0.6010.00 7213.5
3.0 (over 60 min) 2 -4.517.8 0.319.6 -1.319.0 -10.511.4 -0.9510.20 4.410.7
3.0 (over 20 min) 5 10.319.4 8.413.7 9.013.8 -9.914.0 -0.8010.23 8.614.0
3.0 (over 5 min) 8 8.916.3 9.717.6 9.315.9 -12513.9 -0.9010.30 10.416.5
TABLE 2.1:
Maximal changes from baseline in haemodynamic parameters with ascending doses of L-NMMA. To
show the range of changes that occur in normal circumstances in these parameters, the maximal
changes that occurred with placebo in the definitive study are also shown. A = 'change in'; TPRI =
total peripheral resistance index. Values are means ± SD.
(ii) DEFINITIVE STUDY
After the acclimatisation period (see above), subjects received infusion of 0.9% saline
(1 ml min-1) for 30 min followed, in random order, on separate occasions five days
apart, by l-NMMA (3 mg kg-1) or saline vehicle. Both l-NMMA and saline placebo
were given for 5 min at 1.5 ml min-1, followed by further saline infusion (1 ml min-1)
for 85 min.
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2.2.3 Blood pressure and cardiac function
Blood pressure and heart rate (Takeda UA-751 semi-automated oscillometric
sphygmomanometer) (Wiinberg et al, 1988), twelve lead electrocardiograms (ECGs)
(Nihon-Kohden), and bioimpedance measures of cardiac function (stroke index,
cardiac index; BoMed NCCOM3) (Northridge et al, 1990) were recorded at intervals
throughout (Fig. 2.1). In brief, the bioimpedance method uses a constant sinusoidal
alternating current (2 mA RMS, 70 kHz) which is applied between two self-adhesive
Ag-Ag:Cl electrode pairs placed on the left and right lateral aspects of the neck and
lower chest. The voltage associated with this is detected by two inner sensing electrode
pairs placed 5 cm from the corresponding current applying electrodes and parallel to
the current path. This voltage is relayed to an amplifier, and the ECG is signal is
transmitted to a microprocessor within the apparatus. Stroke volume and cardiac index
are calculated by the microprocessor which uses algorithms to produce on-line
measurements of basal impedance, and peak rate of change of impedance which is
dependent upon ventricular ejection time, derived from the ECG. The microprocessor




Where L is the thoracic length estimated from the subject's weight and height using a
nomogram, Z = impedance, dZ/dt [max] is the peak rate of change of impedance
(Bernstein, 1986). Body mass index (BMI) was calculated by dividing the height in
metres by the weight in kilograms squared. Mean arterial pressure was calculated as
diastolic blood pressure + (pulse pressure>+-3. Total peripheral vascular resistance was
calculated as mean arterial pressure/cardiac index, and expressed as dyn min/cm5/m2
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2.2.4 Blood biochemistry and renal function
Each subject had safety tests (sodium, potassium, creatinine, urea, alkaline
phosphatase, alanine transaminase, bilirubin, albumin, calcium and urate; and
haemoglobin, white cell and platelet counts) performed before, and one month after
finishing, the study. On each study day, venous blood and a two-hour urine sample,
collected over the study period, were obtained for estimation of urine flow rate and
creatinine clearance, as well as potassium, sodium and fractional sodium excretion
rates.
2.2.5 DRUGS
Pharmaceutical grade (sterile and pyrogen-free) l-NMMA (Clinalfa AG, Laufelfingen,
Switzerland) was dissolved in physiological saline and infused according to the above
protocol.
2.2.6 STATISTICAL ANALYSIS
All data are expressed as means±SEM (except in the pilot study where means±SD are
given). Data for stroke volume and cardiac output were corrected for body surface
area, calculated to a standard nomogram to provide measures of stroke and cardiac
index. Total peripheral resistance index was calculated as mean arterial pressure
divided by cardiac index, and expressed as dyn min/cm5/m2.
Statistical analyses were performed on untransformed data. Basal values for blood
pressure, heart rate, cardiac function and peripheral vascular resistance were compared
using a one-factor measure analysis of variance. The effect of placebo and l-NMMA
on each of the parameters measured was examined by 2-way repeated measures
analysis of variance. Where analysis of variance showed a significant treatment effect
(P<0.05), placebo and l-NMMA effects were compared at individual time points using
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Student's paired f-test. P-values were corrected for the total number of comparisons by
the method of Bonferroni. Statistical analyses were performed using StatView 512+
software (Brainpower Inc., Calabasas, California, USA) for the Apple Macintosh
microcomputer.
2.3 RESULTS
(i) DOSE-RANGING PILOT STUDIES
At doses <1.0 mg kg"1, there were no apparent trends in the effects for L-NMMA on
haemodynamic parameters, particularly compared with the changes that ocurred with
placebo (Table 2.1). At higher doses, there was an apparent decrease in heart rate and
cardiac index, and an increase in total peripheral resistance, as assessed by the maximal
changes occurring in these parameters. No effect on blood pressure was observed until
a dose of 3.0 mg kg"1 was given over 20 min, when there were isolated increases in
both systolic and diastolic blood pressure (Table 2.1), but these did not occur
consistently at similar time points.
(ii) DEFINITIVE STUDY
2.3.1 Blood pressure and cardiac function
There were no significant differences between basal values for blood pressure, heart
rate or cardiac function for the two study days. Compared with placebo, infusion of
L-NMMA caused a modest, but significant, placebo-corrected increase in mean arterial
pressure of 8±3%, from a value of 84±4 mmHg before dosing (P=0.04; Fig. 2.1).
There was a significant reduction in heart rate of 19±3%, from a predose value of
61±4 bpm (P=0.002). After an initial, non-significant, increase at 5 min, stroke
volume also decreased after L-NMMA, and there was thus a large decrease in cardiac
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index of 21+3%, from a predose value of 3.9±0.3 1 min-1 nr2 (P=0.001). Calculated
peripheral vascular resistance increased by 35±6%, from a predose value of 23±3 AU
(P=0.02), i.e., the biggest effect observed. The haemodynamic changes returned
towards basal values over 90 min (Fig. 2.1).
2.3.2 Blood biochemistry and renal function
Urine flow rate, potassium, sodium and fractional sodium excretion were higher with
L-NMMA than with placebo (Table 2.2), approaching significance for fractional
sodium excretion (P=0.06); creatinine clearance was similar on both days. L-NMMA
did not cause adverse clinical events, alter the electrocardiogram or affect safety tests.
Placebo L-NMMA P value
Urine flow rate (ml min-1) 0.74 ± 0.21 1.23 ±0.43 0.12
Creatinine clearance (ml min-1) 112 ±10 105 ± 10 0.30
Potassium excretion (pmol min-1) 48 ±9 80 ±8 0.13
Sodium excretion (jamol min-1) 87 ±26 138 ±21 0.09
Fractional sodium excretion (%) 0.60 ± 0.21 1.02 ±0.25 0.06
TABLE 2.2:










































i 1 1 1 1 r~








Effects of 3 mg kg-1 L-NMMA given over 5 min (shaded area) on differences from placebo for mean
arterial pressure (MAP, ■), heart rate (HR; A), stroke index (SI; O), cardiac index (CI; •) and
systemic vascular resistance (SVR; □ ). The dashed line represents the last placebo-conected




These findings demonstrate that inhibition of nitric oxide synthesis with L-NMMA
increases blood pressure in healthy human subjects. The 35% increase in calculated
peripheral vascular resistance indicates that the net effect of basal generation of nitric
oxide is to promote vasodilatation, and thereby oppose vasoconstriction in arterial
resistance vessels. The pressor effect would have been substantially greater were it not
for the associated reduction in heart rate, stroke index, and, consequently, cardiac
index; probably mediated through a baroreceptor reflex. It is unlikely that inhibition of
nitric oxide synthesis with L-NMMA reduced cardiac output directly, because nitric
oxide itself reduces contractility of isolated cardiac myocytes (Brady et al, 1992).
Interestingly, stroke volume did increase briefly 5min after administration of
L-NMMA (Fig. 2.1), suggesting that inhibition of cardiac nitric oxide generation may
unmask a negatively inotropic effect of nitric oxide, before baroreflex mediated
suppression of cardiac output develops. The increase in sodium excretion with
L-NMMA, although non-significant, may have been due to a pressure-mediated
natriuresis, or due to intrarenal actions of L-NMMA, and merits further investigation.
It has been suggested that the low systemic vascular resistance and hypotension of
septic shock (Petros et al, 1991) and advanced liver failure (Midgley et al, 1991) may
be due to excess generation of nitric oxide, possibly through endotoxin-mediated
stimulation of the inducible form of nitric oxide synthase (Moncadaet al, 1991). Petros
and colleagues demonstrated an average increase of 22 mm Hg in mean arterial
pressure in two patients with septic shock given a 1 mg kg-1 bolus of L-NMMA
(Petros et al, 1991). However, in the absence of data from healthy subjects, they were
unable to attribute a pathophysiological role to nitric oxide in this disease. The smaller
pressor effect (8 mm Hg) of L-NMMA when given here at a higher dose (3 mg kg1) to
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healthy subjects, confirms that nitric oxide does contribute to the decreased peripheral
vascular resistance and hypotension of septic shock.
Nitric oxide is thought to have many other actions, including regulation of platelet,
kidney and central nervous function (Moncada et al, 1991). Further specific
investigations into the physiological actions of nitric oxide, and the therapeutic uses of
nitric oxide synthase inhibitors, should be facilitated by this demonstration that
L-NMMA is well tolerated in healthy human subjects.
Decreased generation of nitric oxide has been postulated to occur in essential
hypertension (Calver et al, 1992) and chronic renal failure (Vallance et al, 1992). The
large increase in calculated systemic vascular resistance in this study suggests that such
decreased nitric oxide generation may have substantial effects on blood pressure and
tissue blood flow. The likely site of this action, i.e., microvessels which contribute








As discussed in the Introduction (Chapter 1), the potent vasodilator nitric oxide is one
of several mediators important in regulating vascular tone (Vallance et al, 1989;
Haynes & Webb, 1994). In the previous chapter, systemic administration of L-NMMA
increased arterial pressure, and markedly increased systemic vascular resistance,
emphasising the importance of nitric oxide in the regulation of resistance vessel tone.
Microvessels, particularly precapillary resistance vessels, make an important
contribution to peripheral vascular resistance in established essential hypertension
(Shore & Tooke, 1994). Thus, in this chapter, I shall concentrate on an investigation
into the role of nitric oxide in the microvessels of the dermis of the hand.
The anatomy of the skin microcirculation is complex, and regulatory mechanisms
which control blood flow may vary depending on the function of the tissue served.
There appears, for example, to be a role for nitric oxide in the regulation of basal
arteriolar tone in some animal tissues such as the skeletal muscle of the rat cremaster
(Kaley et al, 1992; Sun et al, 1992), and the rabbit (Miigge et al, 1991) and cat
hindlimb (Ross et al, 1991). However, in other tissues, such as the rat mesentery
(Ebeigbe et al, 1990) and the second and third order arterioles of the hamster cremaster
(Hester et al, 1993), nitric oxide appears only to be generated following stimulation by
agonists such as acetylcholine. Moreover, in the hamster cremaster model, in which
different sizes of arteriole were studied, nitric oxide appeared to contribute to basal
tone in larger (65 (im) but not smaller vessels (30 - 45 |im) (Hester et al, 1993). In an
investigation of the control of vascular smooth muscle in the hamster cremaster
microcirculation, de Wit and colleagues (1994) suggest that vasodilators such as nitric
oxide and prostacyclin act synergistically to increase cGMP and cAMP in smooth
muscle, and to inhibit platelet activation. Therefore, these studies in animals suggest
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that the role of nitric oxide in the microcirculation varies between tissues and between
species, and that, even in the same tissue, this variation can depend upon vessel size.
In the human skin microcirculation, an impairment of endothelium-dependent
relaxation has been suggested to cause skin ischaemia in excised skin flaps in vitro
(Kreidstein et al, 1992), and nitric oxide does not appear to have a neurogenic role in
the human skin microcirculation in vivo (Dietz et al, 1994). Although Coffinan and
colleagues (1994) have examined the contribution of nitric oxide to stimulated
sympathetic vasoconstriction, no studies have examined whether basal generation of
nitric oxide is important in the physiological regulation of human skin blood flow.
Arterioles and venules form two plexi in the dermis and it is from the superficial plexus
that the capillary loops of the dermal papillae arise. In those skin areas serving a
primarily thermoregulatory function, such as the finger pulp, arteriovenous
anastomoses are frequently observed whilst other areas, such as the dorsum of the
hand, have few arteriovenous anastomoses and perform a primarily nutritive role
(Clark, 1938). The role of nitric oxide in regulation of blood flow may depend upon
the function of the tissue being studied. I, therefore, investigated blood flow in both
the nutritive tissue of the hand dorsum and finger nailfold, and in the thumb pulp, a
tissue rich in arteriovenous anastomoses. The results suggest that endogenous nitric
oxide production may be more important in regulating microvascular skin blood flow




Six healthy male volunteers (aged 23-35 years), who had given their written,
informed, witnessed consent, took part in this study which was approved by the
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Lothian Ethics of Medical Research Committee. Subjects had not taken prescribed
vasoactive medications in the month before the study, steroidal or non-steroidal anti¬
inflammatory drugs or aspirin in the week before the study; and all had abstained from
food, caffeine-containing drinks, alcohol and smoking for at least 3 h before the study.
3.2.2 EXPERIMENTAL PROTOCOL
The experimental protocol is shown schematically in Figure 3.1. Subjects rested
supine throughout the study with both arms at their sides, slightly bent and supported
comfortably on padded benches. They acclimatised to an ambient temperature of 22-
25°C for 30 min.
(i) Acclimatisation
During acclimatisation, a 27SW-gauge needle (Cooper's Needle Works, Birmingham,
United Kingdom), connected to a 16G epidural catheter (Portex Ltd., Hythe, Kent,
UK), was introduced into a brachial artery under local anaesthesia of 1% lignocaine
(Astra Pharmaceuticals Ltd., Kings Langley, UK). Patency was maintained by
infusion of physiological saline (0.9%; Baxter Healthcare Ltd., Thetford, Norfolk,
UK) at a rate of 1.0 ml min-1 via a Welmed PI000 syringe pump (Welmed Clinical
Care Systems, Bramley, Hampshire, UK. All instruments used to record forearm
blood flow and microvascular measurements were positioned. The left brachial artery
was cannulated in 5 subjects, and the right in 1 subject, due to a failed attempt at the
left. Finger nailfold capillaries of both hands were examined by video microscopy, and
on each hand the finger with the most clearly visible capillaries (usually the ring finger)
was selected for subsequent measurement of capillary blood velocity as detailed below.
To familiarise the subjects with the techniques, recordings of forearm blood flow,
finger blood pressure, red cell flux in the hand dorsum and in the thumb pulp, capillary
blood velocity, skin and ambient room temperature were all performed during this
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FIGURE 3.1:
Experimental design and protocol. Initial recordings made during the Acclimatisation & Cannulation
phase served only to accustom subjects to the techniques, and data were not used in the analysis of
results. Bilateral microvascular recordings (MR) of nailfold capillary blood velocity, hand dorsum and
thumb pulp skin flux, skin temperature and fmger blood pressure were made during each of the
remaining phases as indicated. FBF = forearm blood flow.
(ii) Basal recordings
Once acclimatisation was complete, basal readings ofmicrovascular red cell flux in the
dorsum of the hand and in the pulp of the thumb, measured simultaneously on both
hands, were obtained by laser Doppler fluximetry over a 5 min period. Capillary blood
velocity (basal) was recorded, and the duration of this procedure was dependent upon
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the ease with which high contrast, stable microscopy pictures were obtained and
ranged from 20-30 min. Basal measurements of skin temperature, finger blood
pressure, forearm blood flow, and laser Doppler biological zero, were also obtained,
with forearm blood flow being measured at least 10 min before L-NMMA infusion and
any subsequent microvascular measurement.
(iii) Recordings during drug infusion and recovery periods
L-NMMA was then infused intra-arterially, and microvascular blood flow, finger
blood pressure and skin temperature were monitored during the final 5 min of each
dose. Forearm blood flow and laser Doppler biological zero values (that is, the flux
values obtained without arterial inflow at each of the 4 sites during wrist cuff arterial
occlusion) were measured as soon as possible after the highest dose of L-NMMA
(about 8 min after infusion had stopped). Microvascular blood flow, finger blood
pressure and skin temperature were recorded over the final 20 min of the 30min
recovery period.
3.2.3 FOREARM BLOOD FLOW
The technique of measuring blood flow in limbs has been used for almost a century
(Hewlett, 1909), but modem methods are based on Whitney's technique of venous
occlusion, mercury-in-latex strain-gauge plethysmography (Whitney, 1953). These
older strain-gauges have recently been superseded by indium/gallium-in-silastic
versions which are easier to apply and more readily calibrated. Modem strain-gauge
plethysmography is usually combined with brachial artery infusion of drugs which are
given at local doses, affecting only the forearm vascular bed (Webb, 1995). The non-
infused arm acts as a contemporaneous control throughout the experiment, and
demonstrates that the local doses of drugs used do not produce systemic effects such
as stimulation of neurohumoral reflexes and direct effects on other organs.
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Subjects lay supine with their arms, resting on pillows, inclined at approximately 30
degrees to improve venous drainage. Wrist cuffs were applied and, during the
recording period, were inflated to 220 mm Hg to exclude the hand circulation from the
measurements. Upper-arm congesting cuffs were inflated to 40 mm Hg and blood
flow was recorded for 10 seconds followed by a 5 second refilling period. Multiple 10
second measurements were made over a three minute period and the slopes of the final
5 recordings averaged to determine forearm blood flow. The apparent rate of arterial
inflow to the forearm is disturbed during the first minute after inflation of the high
pressure wrist cuff (Kerslake, 1949). Therefore, blood flow recordings made in the
first minute after inflation were not used in the analysis. Calibration was achieved
using the internal standard of the Vasculab strain gauge plethysmography unit
(MedaSonics, Mountain View, California, USA).
3.2.4 MICROVASCULAR RECORDINGS
(i) Finger blood pressure
Cuffs were positioned on the first finger of each hand, and blood pressure measured
simultaneously using a photoplethysmographic technique (Finapres, Ohmeda,
Englewood, CO, USA). Finger blood pressure measurements by Finapres correlate
with brachial and radial intra-aiterial recordings, and acute changes in arterial pressure
are accurately reflected by the device (Epstein et al, 1991). Two Finapres devices (one
for each hand) were connected via a MacLab (AD Instruments, Castle Hill, NSW,
Australia) digital converter to an Apple Macintosh microcomputer. Using Chart
software (v 3.2.8; AD Instruments, Castle Hill, NSW, Australia), results were stored
for subsequent analysis.
(ii) Skin temperature
Skin temperature was measured at various sites, including the dorsum of the hand, the
volar surface of the forearm and the nailfold of the finger using adherent
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thermocouples (Fluke 52, RS components, Corby UK). Skin temperature, together
with room temperature, was recorded at 5-min intervals throughout the entire study.
(iii) Capillary blood velocity (CBV)
Finger nailfold capillaries were visualised in both hands using two independent,
identical television video microscopy systems as described by Flynn et al (1989) (Fig.
3.2). Each television camera (Phillips LDH0703, KRP Power Source UK Ltd.,
Hambridge Lane, Newbury, UK) was connected to a microscope (Leitz CMM, Leica
UK Ltd., Knowlhill, Milton Keynes, UK), and to a video cassette recorder (Panasonic
AG-7350, KRP Power Source UK Ltd.) so that images could be recorded onto
videotape for subsequent analysis. Finger nailfold capillary loops lie parallel to the
surface of the skin and thus movement of blood cells within the capillaries can be
clearly visualised. Six different microscopy fields, selected sequentially across the
nailfold, were each recorded for 2.5 min.
Continuous measurement of capillary blood velocity (CBV) in the arterial limb of the
capillaries was made by off-line analysis of the video recordings using computerised
photometric temporal correlation (CapiFlow, CapiFlow AB, Kista S-16440 Sweden)
(Fagrell et al, 1994). Two windows were positioned over the arterial limb of a
capillary. Red cells moving up the capillary lumen appear 'black', and are not
recognised by the computer. A photometric signal was generated when the computer
recognised a plasma gap which appears 'white'. The signal detected at the second
window is correlated with the original signal detected at the first. As the distance
between the windows was known, the velocity could be computed. A cross-correlation
limit of 0.4, time constant 2.0 s, and noise limit (delta) of 20 were used. Adequate
cross-correlation is reliant upon a stable image with high contrast, recognisable peaks
and troughs in the photometric signal, and a sufficient length of straight capillary limb
over which to place the photometric windows. Although these criteria are readily met at
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low velocities (<1.0 mm S"1). recognisable fluctuations in the photometric signal at
high flows may be less marked, due for example to changes in orientations or
groupings of red blood cells as they ascend the capillary limb or to lack of plasma
spaces. Thus, in such capillaries, the time during which the correlation reaches the
cross-correlation limit may be low. To minimise variability, subjects were studied at
the same time of day, and at the same environmental temperature, with the author as
the sole investigator. At least 6 capillaries were analysed per subject. To minimise data
selection from capillaries with low velocities, measurement of capillary blood velocity
was attempted in all capillaries which were in focus in each video field, and a capillary
was accepted when adequate correlation was achieved for at least one third of the
recording period. In each capillary in which capillary blood velocity was measured,
red cell column width was also measured at three sites on the arterial limb using a
computerised window splitting technique (CapiFlow, CapiFlow AB, Kista S-16440
Sweden). This represents luminal diameter, assuming that the plasma column does not
alter.
FIGURE 3.2:
Schematic presentation of the videomicroscopy equipment for recording capillary blood velocity.
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(iv) Skin red blood cell flux: dorsal surface of the hand and thumb pulp
Laser Doppler blood flow measurement uses the Doppler shift of laser light. When the
light is reflected off amoving object, its frequency is shifted, with the amount of shift
being dependent on the speed of the moving object. Measurements of skin red cell flux
and red cell concentration were made by laser Doppler fluximeter (MBF3D, Moor
Instruments Ltd., Axminster, Devon, UK), which uses laser light to illuminate skin.
Most of the light will be reflected by static tissue, but some will be reflected by moving
red blood cells. The light reflected by the static tissue and the frequency-shifted light
from moving red cells (Doppler broadening) is collected in a photodetector which
mixes the waves scattered by different structures and detects the intensity of signals
produced. The power spectral density of these signals is determined by the red cell
concentration and velocity (Low et al, 1983). The MBF3D uses a low power laser
(helium/neon; 1.5 mW) to generate one or two (if both channels are being used)
non-injurious beams of infra-red light of wavelength 780-810 nm. Probes contain two
glass fibres: one to transmit, the other to collect reflected light from a single point
(1 mm2) on the skin. The signal is then processed and amplified by a digital processor
to display red cell flux, red cell concentration and mean red cell speed. The mean
Doppler frequency has been predicted to be linearly related to blood flow (Bonner &
Clem, 1981). In vitro studies of red cell blood flow in miniature polythene tubing by
two separate groups have confirmed this linearity (Watkins & Holloway, 1981;
Nilsson et al, 1980). In addition, in vivo studies in human skin (Watkins & Holloway,
1981; Stem et al, 1977), and in pig muscle using 133Xe washout or radioactive
microspheres (Oberg et al, 1979), have also confirmed this linear relationship. Laser
Doppler probes were calibrated before every experiment (Barnett et al, 1990).
Skin red blood cell flux was simultaneously measured, bilaterally, in the dorsal skin of
the hand adjacent to the base of the thumb, and in the thumb pulp. The probe holders
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remained attached to the skin to ensure that flux was measured at exactly the same skin
sites throughout the study. For each laser Doppler monitor, skin red blood cell flux
was calculated using computerised analysis (Moorsoft, Moor Instruments Ltd.) as the
average value over a 5-min period at each point during the protocol (basal, 1, 2, 4
jimol min4 L-NMMA infusion, and recovery).
3.2.5 DRUGS
Pharmaceutical (sterile and pyrogen-free) grade L-NMMA was dissolved in
physiological saline and infused via the brachial artery at a rate of 1.0mlmin4 at three
doses: 1, 2 and 4 (imol min4 (each for 10 min) as an adaptation of a previous protocol
(Vallance et al, 1989).
3.2.6 STATISTICAL ANALYSIS
All data are mean ± SEM. Results are given as percentage change from baseline;
absolute values for all variables measured are given in Table 3.1. The values of the
ratio infused/control were calculated for each subject, and the overall mean calculated
and included in Table 3.1. Previous findings (Flynn et al, 1991) suggested that a
gradual reduction in microvascular parameters occurs with acclimatisation time,
particularly marked for dorsal skin red cell flux and capillary blood velocity.
Therefore, statistical analysis was performed on the ratio infused:control to take into
account such time-dependent changes in the control arm. The ratios of the
microvascular variables were first analysed by repeated measures analysis of variance
(ANOVA). If differences were significant, Student's paired r-tests were used to




3.3.1 FOREARM BLOOD FLOW
Forearm blood flow was reduced by 36.6 ± 3.1%; (95% confidence interval (CI) of
17.0 - 56.2; />=0.005; Table 3.1) following L-NMMA.
3.3.2 MICROVASCULAR RECORDINGS
(i) Finger blood pressure
Finger blood pressure increased during the experiment in both arms. In the control
(F=0.04) and infused (P=0.003) arm, this increase with time was significant.
However, the difference between the two arms was not significant (F=0.87; Table
3.1).
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Variable Arm Basal 1 ^moi min'1 2 /xmol min'1 4 /xmol mln'x Recovery ANOVA
Forearm blood flow








Finger blood pressure I 9615 10015 10316 10616
(mean arterial pressure/mm Hg) C 9215 9615 9615 10014




Pulp red cell flux
(AU)
Ratio
I 210151 199157 156154 158154 163150
C 208156 216150 200144 199145 209151
1.2610.25 1.0910.22* 0.8910.21** 0.8410.16* 0.9510.23* P=0.0001
Dorsum red ceil flux
(AU)
Ratio


















Capillary blood velocity I 1.1110.17 1.1110.20 0.9310.13 0.9310.23 0.9010.17
(mm s"1) C 1.0910.19 1.0710.22 0.9810.21 0.9210.22 0.8710.20



































Results for forearm blood flow, finger blood pressure, and for microvascular measurements, including
values for skin temperature in the infused (I) and the control (Q arm. Results from each subject were
averaged to give mean ± SEM. Ratios for each subject were calculated individually and expressed as
mean in the table.
(ii) Skin temperature, capillary blood velocity, red cell column width,
hand dorsal skin red blood cell flux, thumb pulp red cell flux
As expected (see above), dorsal skin temperature, red cell flux and capillary blood
velocity fell gradually over the experimental period (Table 3.1). However, these time-
related effects did not differ in the control arm compared to the arm infused with
L-NMMA for dorsal red cell flux and capillary blood velocity (Fig. 3.3), or for red cell
column width and skin temperature. In contrast, L-NMMA markedly reduced thumb
pulp red cell flux (P=0.0001: Fig. 3.3; Table 3.1).
FIGURE 3.3:
Capillary blood velocity (A), red blood cell flux in the dorsum of the hand (0) and finger pulp (•),
are shown as % A of rauo infused: control arm from baseline. The difference between the effects of the
3 doses of l-NMMA (shown on the horizontal axis) on red cell flux in the dorsum and the pulp
(ANOVA: P=0.037) is shown by asterisks.
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3.3.3 Laser Doppler biological zero values
Biological zero, on either the pulp or dorsal site, was similar between individuals and
was not changed by the L-NMMA infusion (pulp 12.8 ± 2.6 arbitrary units (AU)
basal, 12.6 ± 2.5 AU 2-5 min post infusion; dorsum 5.4 ± 1.6 AU basal, 4.9 ±1.6
AU 2-5 min post infusion), nor did biological zero differ in the two hands either before
or after the infusion, (basal: thumb pulp 12.3 ± 2.2 v 13.2 ± 3.2 AU; dorsum: 5.5 ±
1.7 v 5.3 ± 1.7 AU; post infusion: thumb pulp: 11.9 ± 2.2 v 13.2 ± 2.9 AU; dorsum:
4.8 + 1.6 v 5.0 ± 1.8 AU). The contribution of biological zero to the flux signal was
relatively small, 7.3 ± 1.4% and 15.4 ± 1.2% of pulp and dorsum red cell flux
respectively during basal measurements. Therefore, since the effects of biological zero
are small in these circumstances (the maximum effect of subtracting biological zero
would be a change in ratio by 0.2, or an alteration of percentage change by 6%), and
biological zero cannot be measured at each time point throughout the experimental
protocol, flux data are expressed without subtraction of biological zero.
3.4 DISCUSSION
These data show that doses of L-NMMA producing substantial reduction in forearm
blood flow had no effect on red blood cell flux in the dorsal skin of the hand or on red
blood cell velocity in nutritive nailfold capillaries. In contrast, red cell flux in the finger
pulp, an area rich in arteriovenous anastomoses, was substantially reduced. This
suggests that in the human skin microcirculation, endogenous nitric oxide plays a
greater role in regulation of blood flow in areas rich in vessels with a mainly
thermoregulatory function than in areas rich in vessels serving a primarily nutritive
role.
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All measurements were made in both the infused and contralateral arm; the latter acting
as a contemporaneous control throughout the experiment so that physiological
fluctuations in all parameters measured could be taken into account. This is based on
evidence that micromolar doses of L-NMMA infused via the brachial artery exert a
local effect only (Vallance et al, 1989). In addition, these doses are sufficient to
substantially block the vasodilator response to acetylcholine (Chowienczyk et al,
1993), and that doses required for systemic effects are much higher (Chapter 2;
Section 2.2.2; Stamler et al, 1994). The small increase in finger blood pressure in both
arms was probably due to mild sympathetic activation associated with this slightly
stressful study. Due to the hand ischaemia caused by the measurements of forearm
blood flow, it was not considered possible to obtain measurements of forearm blood
flow during L-NMMA infusion without jeopardising the measurements of
microvascular flow which this study was primarily designed to examine. Therefore,
forearm blood flow was measured shortly after L-NMMA infusion was stopped. When
this difference in timing is taken into account, the effects of L-NMMA are similar to
those reported by other workers using the same dose (Vallance et al, 1989; Calver et
al, 1992).
Skin blood flow is variable from site to site and to a considerably lesser degree from
moment to moment (Braverman & Schechner, 1991). The laser Doppler technique can
also detect reductions in nutritive flux; for example, during finger cooling or changes
in posture (Hassan & Tooke, 1988). However, there was no such reduction in the skin
of the hand dorsum following L-NMMA infusion. In the present study, variability was
minimised by using the same skin site to monitor red blood cell flux throughout the
study, by obtaining an average flux value over at least a 5 min period, and, in the case
of capillary blood velocity, by studying the same capillary for as many of the
experimental periods as possible and for as long as possible (Fagrell et al, 1994).
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The skin microcirculation has a complex architecture. The finger pulps and nailbeds are
areas rich in arteriovenous anastomoses, conspicuous by their thick muscular walls
and tortuosity (Grant & Bland, 1931); these are highly innervated and serve a
thermoregulatory function (Clark, 1938). These vessels provide an alternative pathway
from the arterial to the venous circulation, bypassing the terminal capillary bed. In
contrast, arteriovenous anastomoses are infrequent on the dorsum of the hand or finger
nailfold. Thus, as a result of this difference in skin architecture, the two skin sites we
investigated may differ, firstly in the degree of neurogenic tone of the vessels, and
secondly in the size of the blood vessels from which the laser Doppler signal is
derived. In areas lacking arteriovenous anastomoses, the laser Doppler signal is
derived from capillaries, arterioles and venules. However, as capillary flow accounts
for around 10% of blood flow to the skin in these areas, the majority of the laser
Doppler signal is derived from other vessels.
Studies in animals suggest that there may be interactions between endothelial release of
nitric oxide and the perivascular nerves (Tesfamariam & Cohen, 1988). The overflow
of noradrenaline from perivascular nerves was reduced in the presence of an intact
endothelium in both the rabbit carotid and the canine pulmonary artery studied in vitro,
suggesting that the endothelium may influence neurotransmission by a prejunctional
mechanism (Tesfamariam et al, 1989). In addition, noradrenaline-stimulated release of
endothelial derived relaxing factors may attenuate the mediated neurogenic
vasoconstriction at the level of the smooth muscle cell. If basal release of nitric oxide
opposes the tonic adrenergic vasoconstriction in human hand skin microcirculation,
inhibition of nitric oxide synthase by L-NMMA would be expected to reduce skin
blood flow particularly in areas of high basal flow or resting tone, including the finger
pulp, in keeping with the results of the present study.
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Alternatively, these findings may reflect differences in vessel size, wall thickness, or
function in the two skin areas. In animals, the role of nitric oxide as a regulator of
basal tone is more marked in the larger arterioles of the hamster skeletal muscle
microcirculation than in the smaller vessels (Hester et al, 1993) and similar findings
have been reported for the rabbit ear branching arteries (Griffith et al, 1987). Whether
such a size-determined differential control occurs in the human skin microcirculation,
and whether it contributes to our findings, is unclear. Computerised models suggest
that alterations in walklumen ratio may alter the change in resistance for a given degree
of vascular smooth muscle shortening or lengthening (Egan et al, 1988). Such a
mechanism may contribute to the observed greater fall in blood flow in the area rich in
arteriovenous anastomoses in the present study, since the thicker walled arteriovenous
anastomoses might be expected to have a larger increase in vascular resistance as
smooth muscle shortens.
Finger nailfold capillary red cell velocity was unaltered by L-NMMA infusion. As red
cell column width was also unchanged during the infusion, it is likely that capillary
blood velocity reflected capillary blood flow. Increases in vascular resistance
proximally may be compensated for by a reduction in resistance nearer the capillary
level in an attempt to maintain nutritive capillary flow. These results confirm the more
indirect laser Doppler assessments of dorsal hand skin, and suggest that either nitric
oxide is not involved in the regulation of basal capillary nutritive flow, or that other
mechanisms become operative and serve to compensate for the loss of endogenous
nitric oxide.
Possible alternative explanations for these findings might relate to the differences in
blood flow between the two skin areas. Blood flow to the finger pulp is considerably
greater (about fivefold) than that to the dorsal regions of the hand. Thus, it is likely that
L-NMMA would reach the pulp areas before reaching the nutritive areas, and that a
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greater total amount of L-NMMA would be delivered to the pulp areas during the
30-min infusion. The exact relationships between rate of delivery, total dose of
L-NMMA delivered to an area, basal levels of nitric oxide and the vasodilatory
response to L-NMMA are unknown, but may provide a potential explanation for my
findings. Alternatively, the higher flow rates to the pulp may result in a greater flow-
dependent release of nitric oxide under basal conditions, and thus a greater inhibition
by L-NMMA. Although there is some evidence that flow-dependent vasodilatation may
occur in the forearm vascular bed, it has not been well described in human skin. In
animals, it appears that the mediators involved in such flow-dependent vasodilatation
may vary according to vessel size and vascular preparation. Whether or not this is the
case in man is unknown. Because of the demanding nature of this study, and the
requirement for duplicate apparatus and a second operator (AC Shore) so that the
infused and non-infused arm could be studied simultaneously, I did not include a
phase using a control vasoconstrictor such as noradrenaline, although this is a future
possibility.
In the previous chapter, the global haemodynamic effects of systemically administered
L-NMMA, indicated the relevance of nitric oxide to the maintenance of vascular tone
and the control of blood pressure. The microcirculation in resistance beds makes the
greatest contribution to peripheral vascular resistance. In the present chapter, therefore,
I have focused on skin microvessels, investigating mechanisms underlying these
systemic effects. Using pharmacological, microscopic and laser Doppler techniques,
the results of the present study suggest that vascular resistance in the skin
arteriovenous anastomotic pathway is increased by L-NMMA, although changes in
resistance sufficient to reduce flow are not apparent in areas of mainly nutritive flow.
Basal absolute flow was higher in the pulp than in the dorsum, and it may be that
L-NMMA inhibited flow-induced release of nitric oxide (Rubanyi et al, 1986b). Thus,
the investigations in this chapter have focused on nitric oxide as a mediator of
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endothelium-dependent vasodilatation. The possible contribution from other mediators








In the studies discussed so far, I have concentrated on investigating the physiological
role for nitric oxide in healthy individuals. In this chapter, the pharmacology of
endothelial function is investigated in blood vessels of the skin microcirculation, using
the non-invasive, in vivo technique of drug iontophoresis. In subsequent chapters, this
investigation will be extended to include alterations in endothelial function in
hypercholesterolaemia and hypertension.
Previous investigations of endothelial function have relied on the invasive technique of
arterial infusion of dmgs, limiting the numbers of subjects that could be easily studied.
4.1.1 Iontophoresis
The principle of drug iontophoresis is that an electrical potential difference will actively
cause ions in solution to migrate according to their electrical charge (Figure 4.1). As
well as charge, the quantity and distribution of a drug delivered by iontophoresis is
dependent upon molecular weight of the drug, magnitude and duration of the current
applied, electrode composition (Yoshida & Roberts, 1992), and the site of
iontophoresis.
The main barrier to topical application of drugs is the stratum corneum. When this is
stripped from the skin, negligible resistance to ion flow is achieved (Wearley et al,
1989). However, when a potential gradient is established across skin with an intact




Schematic diagram of the iontophoretic delivery of drug ions from the chamber (the anode in this
case). Current is delivered by an iontophoretic device which is connected to and computer from where
it is controlled. The computer is also used to perform the analysis.
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In his classic experiment, Leduc (1900) connected two rabbits in series to an electrical
generator (Fig. 4.2). The first rabbit was connected to the machine via an electrode
containing strychnine sulphate (positive electrode). The electrode connecting the
second rabbit to the machine contained potassium cyanide (negative electrode). To
complete the circuit, the rabbits were connected to each other by a water electrode.
Leduc's classic experiment. Two rabbits are placed in series with the same direct current circuit, with
strychinine sulphate as the positive electrode and potassium cyanide as the negative electrode.







When a current of 40 - 50 mA was delivered the first rabbit was seized by tetanic
convulsions due to the strychnine, while the second rabbit died from cyanide
poisoning. However, when the two rabbits were replaced, and the direction of current
reversed, neither animal was harmed.
Due to a technological inability to provide controlled iontophoretic delivery of drugs,
iontophoresis went out of favour. More recently, many animal models have been used
in vitro for iontophoretic drug delivery studies, including permeability studies in the
hairless mouse (Burnette & Ongpipattanakul, 1987; Pikal & Shah, 1990), hairless
guinea pig (Behl et al, 1989), and the hairless rat (Wearley et al, 1989 and 1990).
From their initial investigation of skin permeability, ion transport mechanisms, and
quantification of ions transferred across the skin, these studies aimed to establish
iontophoretic delivery as an alternative route for therapeutic drug administration (see
below). In vivo experiments have been performed to quantify delivery of simple
inorganic ions in the pig (Phipps et al, 1889), to deliver a dobutamine analogue in the
dog (Sanderson et al, 1987), radiolabelled dexamethasone in the monkey (Glass et al,
1980), and insulin in the rabbit (Meyer et al, 1989),
In humans, use of the technique as a means of actively delivering therapeutic agents
locally has been of interest to dermatologists (for reviews, see Glass et al, 1980; Singh
& Maibach, 1993 & 1994). Its success in delivering anticholinergic agents such as
poldine methyl sulphate (Hill, 1976), glycopyrronium bromide (Abell & Morgan,
1974), and atropine (Gibinski et al, 1973) in treating hyperhidrosis (for review, see
Sloan et al, 1986) has made it well-established in clinical practice.
Iontophoresis of drugs for their local effects has also been combined, for investigative
purposes, with transcutaneous electrical nerve stimulation (TENS) to examine
neuropeptide release from specific stimulation of polymodal C-nociceptors (in sensory
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C-fibres) which terminate just below the stratum corneum (Gamsworthy et al, 1988;
Westerman et al, 1988). Neuropeptides released include substance P and calcitonin
gene-related peptide (CGRP), which were studied in relation to the development of
erythematous wheals (Brain & Edwardson, 1989). The TENS technique has also been
combined with iontophoresis in an investigation of neurovascular function in diabetes
mellitus (Westerman et al, 1988). Although these investigative studies may be useful in
neurophysiology, they do not examine the effects of drugs on microvascular blood
flow, or the pharmacological mechanisms involved.
In addition, recent studies have investigated iontophoresis as a method for delivering
drugs systemically, e.g., verapamil (Wearley et al, 1988), propranolol (Padmanabhan,
1986), dexamethasone (Glass et al, 1980), and peptides such as insulin (Chien, 1987;
Meyer et al, 1989), arginine-vasopressin (Waud, 1967; Benaijee & Ritschel, 1989;
Craane-van Hinsberg, 1994), and gonadotropin-releasing hormone (Miller et al,
1990). However, the duration of iontophoresis is often several hours before drug
concentrations become measurable in plasma (Singh et al, 1995). Further, in
administering drugs systemically using this method, benefits include circumventing
hepatic first-pass metabolism through controlled delivery, for example, to reduce toxic
effects of drugs such as azidothymidine (AZT) used in the treatment of AIDS (Wearley
& Chien, 1990).
4.1.2 Iontophoresis in assessing endothelial function
Despite these extensive studies, no studies have examined the pharmacological
mechanisms underlying the vasodilatation of dermal vessels in response to vasoactive
agents such as acetylcholine and sodium nitroprusside. The previous two chapters
have focused on the importance of nitric oxide in vascular homeostasis. However, as
discussed in Chapter 1, cholinergic vasodilatation is dependent on a functioning
vascular endothelium but may be mediated by generation of mediators other than nitric
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oxide, such as prostacyclin or EDHF. In the present studies, the aims were: (i) to
investigate whether iontophoresis of vasodilators acetylcholine and sodium
nitroprusside would produce increases in blood flow in skin microvessels and whether
these could be assessed, quantitatively, by laser Doppler fluximetry; (ii) to use nitric
oxide synthase and cyclooxygenase inhibitors to investigate the pharmacological
mechanisms of cholinergic vasodilatation in the dermal vessels; (iii) to establish
whether the non-invasive technique of transdermal iontophoresis combined with laser




Ten healthy men (aged 23-39 yr) took part in the pilot studies; 6 (aged 23-35 yr) in the
later studies with L-NMMA and noradrenaline; and a different group of 6 (aged 25-36
yr) in the aspirin study. All participants gave their written, witnessed, informed
consent to participate in these studies which were approved by the Lothian Ethics of
Medical Research Committee. They abstained from food, caffeine-containing drinks,
alcohol and smoking for at least 4 h before each study.
4.2.2 EXPERIMENTAL PROTOCOL I: IONTOPHORESIS PILOT
STUDIES
Subjects acclimatised to an ambient temperature of 22-25°C for 30 min, and rested
supine throughout the recordings. The skin was cleansed with an isopropyl alcohol
swab at the beginning of acclimatisation, and left undisturbed for at least 10 min before
attaching a perspex iontophoresis chamber (Moor Instruments Ltd., Millwey,
Axminster, Devon, UK), using a double-sided adhesive ring, to the volar aspect of the
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right arm. A thermocouple was taped to an adjacent site, so that skin temperature could
be monitored throughout iontophoresis experiments and maintained above 32°C
(Westerman et al, 1988; and personal communication). Using a 2 ml syringe without a
needle, 0.25 ml vehicle or drug was injected into the iontophoresis chamber. A laser
Doppler probe was then inserted, to measure flux continuously during each sequence
(see below) by laser Doppler fluximetry (described in detail in Chapter 3; Section
3.2.4; p 48). Data were downloaded onto a personal computer for subsequent
computerised analysis (Moorsoft V4.241, Moor Instruments Ltd.). The chamber was
then removed and cleaned before the procedure was repeated on a neighbouring site
with the next solution.
(i) Iontophoretic charge
In delivering drugs across the skin, iontophoresis is based on the principle that the
magnitude of an electrical charge (Q) is dependent on the length of time (t) a current (/)
is passed (Q = It). To ensure minimal discomfort to subjects, small currents (100 -
200 pA; see below) were applied for 10 - 80 s. After agents for iontophoresis were
injected into the chamber, and the probe inserted, iontophoresis was started (Moor
Iontophoresis Controller 1, Moor Instruments Ltd.) with currents of 100 or 200 p.A,
of increasing duration (100 pA for 10 s; 200 pA for 10 s; 200 pA for 20 s; 200pA for
40 s; and 200 pA for 80 s) such that charges of 1, 2, 4, 8 and 16 mC were applied.
Response periods were allowed after each charge, before the start of the next: 60 s for
1 and 2 mC, 90s for 4 mC, 120 s for 8 and 16 mC, as these were sufficient to record
maximal values before a return toward baseline (Fig. 4.5).
(ii) Vehicle pilot study
Before iontophoresing drugs, an inert vehicle had to be developed and validated.
Using the protocol for iontophoretic charge described above, saline (0.9%) was
iontophoresed (Fig. 4.3). As vasodilator responses to saline alone were elicited from
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the lowest iontophoretic charge upwards, saline was replaced by tap water and the
protocol repeated. Tap water also caused vasodilatation, albeit at higher iontophoretic
charges, and was replaced by distilled, de-ionised, HPLC-grade water (Rathburn
Chemicals Ltd., Walkerburn, Scotland, UK). This still caused some effect at the
higher charges and, in addition, induced slight pain at the site of iontophoresis. No
bums occurred, but a painless erythematous weal was produced, subsiding after 1-2
hours. Next, methylcellulose gel was reconstituted using the same distilled, de-ionised
water to give a 4% concentration. The gel was left to set in a refrigerator overnight
before use, and stock solutions subsequently stored at 4°C. This vehicle did not cause
responses at 1, 2, 4 and 8 mC (Fig. 4.3) irrespective of the direction of the current,
and was adopted into the protocol. In addition to being iontophoretically inert, the gel
provided a stable medium for drug handling which enabled controlled transdermal












Development of an inert vehicle for drug iontophoresis. Responses to saline (■), tap water (•),
distilled, de-ionised, HPLC-grade water (O), and methylcellulose gel (2%) reconstituted in distilled,
de-ionised, HPLC-grade water (□).
(ii) Drug concentrations
Acetylcholine was used as an endothelium-dependent, and sodium nitroprusside as an
endothelium-independent, vasodilator. For iontophoresis, acetylcholine (Sigma
Chemicals Ltd., Poole, Dorset, UK) was weighed (50 mg) and dissolved in de-
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ionised, distilled water (1.25 ml) to give a 4% solution. Immediately before each
study, this was mixed 1:1 in the de-ionised vehicle (above) to give a final 2% working
solution. Sodium nitroprusside (50 mg) (Nipride, Roche Pharmaceutical Products
Ltd.) was reconstituted in exactly the same way immediately before each study, to give
a 4% solution. This was mixed 1:1 in the de-ionised vehicle (above) to give a final 2%
working solution. In the initial studies, these drugs were iontophoresed at even lower
concentrations (1%) by doubling the volume of water and gel at the time of
reconstitution. Maximal responses were achieved with 2% concentrations using the 1-8
mC charge range, whereas 1% concentrations required an additional charge (16 mC) to
acheive the maximum response (Fig. 4.4). At 16 mC, vehicle alone began to elicit
responses. Therefore, 2% concentrations delivered from 1-8 mC were used in all later
studies. This protocol gave intra-individual and inter-individual coefficients of
variation of 34±4 and 41±5% for acetylcholine, and 34±4 and 29±3% for sodium
nitroprusside respectively for iontophoretic drug delivery. Acetylcholine, sodium
nitroprusside and vehicle were applied in this way in random order in all experiments.
Mean flux, measured at the plateau of the response for each drug charge, was
expressed in arbitrary units (AU). A typical trace for acetylcholine 2% is shown in
Fig. 4.5.
4.2.3 LASER DOPPLER BIOLOGICAL ZERO
Laser Doppler biological zero values were recorded at each iontophoretic site by
recording flux during inflation of an upper arm cuff to 220 mm Hg. However, the
range of biological zero values obtained was low (between 4.5 and 13.1; mean
7.48±0.32 AU). These values are negligible in relation to the vasodilatation to
iontophoresed drugs (Table 4.1; Figs. 4.3 and 4.4), thus, they were not taken into








1 2 4 8 16
Iontophoretic charge (mC)
FIGURE 4.4:
Using 2% (•) concentrations, there is a leftward
acetylcholine compared with 1% (■).
shift in the iontophoretic response curve for
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FIGURE 4.5:
Laser Doppler blood flow trace during the iontophoresis of acetylcholine 2% in a healthy individual.
The sequence shows flux measured in arbitrary units (vertical axis), against time in minutes
(horizontal axis). Iontophoretic charges in millicoulombs (mC) are shown above the sequences.
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4.2.4 EXPERIMENTAL PROTOCOL II: DEFINITIVE STUDIES
Effect of L-NMMA and noradrenaline
This was a two phase, randomised, single-blind crossover study, separated by 14
days, in 6 healthy male subjects. Following cannulation of the left brachial artery
(Chapter 3; Section 3.2.3; pp 44-45), basal forearm blood flow was recorded in both
arms during 0.9% saline infusion (at 1 ml min-1). Acetylcholine and sodium
nitroprusside were prepared and iontophoresed according to the protocol described
above, with the modification that each drug (order randomised) was iontophoresed in
both arms simultaneously using two identical iontophoresis controllers. In one phase,
L-NMMA (Chapter 3; Section 3.2.5; p 49) dissolved in physiological saline, was
infused via the brachial artery at a rate of 1.0ml min-1 at 4 jimol min-1 (for 30 min)
while iontophoresis was performed and then forearm blood flow measurements
repeated in the final 5 min. In the other phase, noradrenaline (Levophed, Sanofi
Winthrop Ltd., Guildford, Surrey, UK), prepared in 0.9% saline, with ascorbic acid
(10 fig ml"1) as an anti-oxidant, was infused at increasing doses (60-480 pg ml*1)
(Walker et al, 1992) until 40% vasoconstriction was achieved to match the L-NMMA
effect. Noradrenaline is a catecholamine derived from the amino acid L-tyrosine,
released from sympathetic post-ganglionic nerve terminals. It is a potent agonist at
a-adrenoceptors, causing constriction of vascular smooth muscle (Weiner, 1985)
independently of the endothelium. The infusion was then continued for 20 min while
iontophoresis was repeated, at least 10 min after the last forearm blood flow recording.
Effect of aspirin
This was a two phase, randomised, single-blind crossover study in 6 healthy male
subjects. In one phase, iontophoresis of acetylcholine and sodium nitroprusside (order
randomised) was performed in the right arm, before and after bolus intravenous
injection of aspirin (Aspegic; Laboratories Synthelabo, Paris, France) (600 mg in 5 ml
water for injection), via a vein in the antecubital fossa. Aspirin is the acetyl ester of
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salicylic acid, and was used because it is a potent, irreversible inhibitor of cyclo-
oxygenase, the enzyme responsible for the production of prostaglandins and
thromboxanes (Vane, 1971; Roth, 1975; Barrow, 1988), achieving almost total
inhibition 30 min after administration (Heavey, 1985). In the other phase,
iontophoresis of the same agents was performed before and after 0.9% saline placebo
injection. Phases were separated by 14 days.
4.2.5 FOREARM BLOOD FLOW AND DRUG INFUSION
Basal forearm blood flow was measured in both arms simultaneously by venous
occlusion plethysmography as previously described (Chapter 3; Section 3.2.3; pp 44-
45). In the L-NMMA phase, forearm blood flow was then measured about 30 min after
the start of infusion, i.e., as soon as iontophoresis was finished. In the noradrenaline
phase, once a 40% reduction in flow was achieved, a period of 10 min was allowed
before starting iontophoresis. Final forearm blood flow measurements were then
made, before stopping the infusion. Forearm blood flow is given as the ratio of flow in
the infused arm to that in the control arm, expressed as percentage change from
baseline.
4.2.6 STATISTICAL ANALYSIS
Data are represented as mean±SEM. Analysis of iontophoretic response curves was by
repeated measures analysis of variance.
4.3 RESULTS
4.3.1 EFFECT OF L-NMMA AND NORADRENALINE
L-NMMA caused a reduction of forearm blood flow in the infused arm (4.4±1.3 to
2.4±0.8 ml 100 ml-1 min-1) but did not affect flow in the control arm (3.6±0.8 to
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3.6±0.5 ml 100 ml"1 mirr1). The ratio of flow in the infused:control arm was 1.2±0.2
before and 0.710.2 ml 100 ml4 min4 during L-NMMA infusion, giving a percentage
fall from baseline of 4312% (P=0.001). The effect of noradrenaline was well-matched
since it caused a reduction in forearm blood flow in the infused arm (3.610.7 to
2.010.5 ml 100 ml4 min4) but not in the control arm (2.610.4 to 2.710.6 ml 100 ml4
min4). The ratio of flow in the infiosed:control arm was 1.410.2 before and 0.810.2
during noradrenaline infusion, i.e., a reduction of 4412% (P=0.001).
Brachial artery infusion of L-NMMA or noradrenaline did not alter the response to
iontophoresis of acetylcholine and sodium nitroprusside in the infused arm (Table 4.1
and Fig. 4.6), and responses were similar to those recorded in the control arm.
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acetylcholine
Basal 1 mC 2mC 4mC 8mC
sodium nitroprusside
Basal 1 mC 2 mC 4 mC 8mC
L-NMMA
Flux infused arm (before)
Flux infused arm (during)
Flux control arm (before)
Flux control arm (during)
2615 126142 232±54 324±72 360180
39±11 131±43 239±61 332±76 3951102
40±15 141±55 213±58 310159 337±48
43±7 245±58 378±84 451±99 497±99
52110 94119 240163 399193 4941119
2916 73131 140148 257160 366179
63121 112145 202184 308182 365175
46114 111154 180173 3241105 4381115
Ratio (infused/control) 1.310.2 1.0±0.5 1.3±0.7 1.010.3 0.910.2 0.710.1 0.810.3 0.810.3 0.810.2 0.710.2
Noradrenaline
Flux infused arm (before)
Flux infused arm (during)
Flux control arm (before)
Flux control arm (during)
3218 120136 218139 296140 342140
57113 117117 252148 300155 366169
3918 226127 346154 449193 469199
46113 171169 3221110 3951115 4331112
64122 95141 149151 276151 342158
51115 79130 151135 236137 335154
4619 134181 2101108 335197 394195
4119 91153 203178 339197 4241103




3212 211172 347169 408176 473181
35110 119125 177134* 204137* 222143*
3116 80130 142146 260162 302159
4016 117126 203138 306155 355158
Ratio (Post aspirin/pre
aspirin)
1.110.3 0.810.2 0.510.1 0.510.1 0.410.1 1.610.4 3.011.0 3.011.7 1.510.4 1.310.3
TABLE 4.1:
Iontophoretic responses to acetylcholine and sodium nitropmsside before and after brachial artery
infusion of L-NMMA or noradrenaline, and before and after bolus intravenous injection of aspirin.
Results for skin flux from each subject were averaged to give means ± SEM in arbitrary units of flux
(AU). Ratios for each subject were calculated individually and expressed as means in the table. For the












Vasodilatation during iontophoresis of acetylcholine before (■) and during (□) brachial artery
infusion of L-NMMA. Units of flux are given as arbitrary units (AU).
4.3.2 EFFECTS OF ASPIRIN
Aspirin inhibited the vasodilator response to acetylcholine (Fig. 4.7), but did not affect
the response to sodium nitroprasside (Table 4.1). Placebo injection had no effect on











Vasodilatation during iontophoresis of acetylcholine before (■), and 30 min after (□), intravenous
injection of aspirin (600 mg). Reduction in flow by aspirin was significant (P<0.01). Units of flux are
given as arbitrary units (AU).
4.4 DISCUSSION
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Acetylcholine and sodium nitroprusside produced dose-related increases in blood flow
in skin microvessels measured, quantitatively, by laser Doppler fluximetry. Neither the
nitric oxide synthase inhibitor, L-NMMA, nor the non-selective a-adrenoceptor
agonist, noradrenaline, infused via the brachial artery, had any effect on responses to
iontophoresed acetylcholine or sodium nitroprusside in forearm dermal vessels.
Aspirin, but not placebo, markedly reduced cholinergic vasodilatation in dermal
vessels. This non-invasive protocol, therefore, measures cholinergic vasodilatation in
human dermal vessels, and includes the most favourable electrical charges for drug
delivery without discomfort to subjects. No non-specific response to iontophoresis
was observed with the charges used, combined with a non-ionic vehicle. By keeping
currents low while increasing the duration of iontophoresis, thermally-induced axon
reflexes were avoided. Thus, by preventing substance P release, and the inflammatory
response to pain, mediated by vasoactive agents such as bradykinin and histamine
(Magerl et al, 1990; Westerman et al, 1990), vessels were not induced to become more
permeable (Low & Westerman, 1989).
This technique was used to investigate the mechanisms of cholinergic vasodilatation in
dermal vessels. Responses to sodium nitroprusside in dermal vessels were unchanged
following brachial artery infusion of L-NMMA and noradrenaline, or systemic
administration of aspirin. In contrast, vasodilatation in response to acetylcholine was
inhibited by aspirin but not by L-NMMA, suggesting that it is, at least in part, mediated
by vasodilator prostanoids. There remained an element of cholinergic vasodilatation
which is not inhibited by aspirin (approximately 44%). This may be because nitric
oxide or EDHF generation may contribute more importantly to cholinergic
vasodilatation when prostacyclin generation is inhibited. These results with
iontophoresis are analogous to findings in renal arteries where prostacyclin is an
important mediator of vasodilatation (Breierwates et al, 1982; Ito et al, 1989), and to
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findings in the perfused rat superior mesenteric arcade in vitro, where cholinergic
dilatation is inhibited by inhibitors of prostanoid synthesis, dexamethasone and
indomethacin, but not by the nitric oxide synthase inhibitor, L-NAME (Walker et al,
1995).
Previous studies which have used intra-arterial infusion of drugs combined with blood
flow measurements in the forearm, have equated endothelial dysfunction with an
impairment in basal (Calver et al, 1992a; Panza et al, 1993a) and stimulated (Panza et
al, 1990; Linder et al, 1990) nitric oxide generation. Although iontophoresis provides a
non-invasive method of investigating endothelial function, it would appear to be
assessing a different pathway. This is consistent with findings from the previous
chapter, which suggested that mechanisms of vasodilatation may be dependent on the
size and rate of blood flow through the vessels, and on the particular tissue being
studied. Further investigation into the pharmacological mechanisms of vasodilatation in
skin microvessels, using this non-invasive technique, is required before iontophoresis
may be useful, in the long term, in studying large groups of patients in epidemiological
and clinic-based research.
The contribution from EDHF to iontophoretic vasodilatation has not been investigated,
and its importance could be investigated by iontophoresis in the combined presence of
aspirin and L-NMMA. If an element of vasodilatation were to remain in the presence of
these inhibitors, and could be abolished with a potassium channel blocker such as
tolbutamide, the contribution from EDHF could be confirmed.
With the proviso that the mechanisms underpinning the technique require further
investigation, iontophoresis may have potential in studying patients. Patients who have
impaired nitric oxide generation as assessed by the 'gold standard' intra-arterial
technique, may also have an impaired prostacyclin generation in skin microvessels. If a
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correlation exists, iontophoresis may be useful as a marker of, for example,
atherogenesis in hypercholesterolaemia, as endothelial dysfunction is known to exist in
this condition long before any evidence of the presence of atheroma (Rabbani &
Loscalzo, 1991; Arcaro et al, 1995). As the principal mechanism of vasodilatation in
forearm dermal vessels would appear to be prostanoid-mediated, iontophoresis could
complement the intra-arterial method of investigating endothelial dysfunction, by
assessing a different pathway of cholinergic dilatation. Such an investigation, in








Along with diabetes mellitus, obesity, smoking and left ventricular hypertrophy,
hypertension and hypercholesterolaemia are major risk factors associated with
atherosclerotic vascular disease (McMahon & MacDonald, 1986; Dollery, 1987).
These factors co-segregate in the population and act synergistically in enhancing the
risk of coronary artery disease. In particular, hypertension and hypercholesterolaemia
interact closely in potentiating atherogenesis.
A balance exists among haemodynamic factors, serum lipids, platelets, and the blood
vessel wall. Alterations in this balance may favour atherosclerosis. Endothelial cells act
not only as a lining for blood vessels, but also have many functional roles (Chapter 1;
Sections 1.2.1, 1.2.5 and 1.2.6) which, when perturbed, may participate in
atherogenesis (Gimbrone, 1976). These functions include the provision of a non¬
adherent surface for leukocytes and platelets; a permeable barrier that controls the
exchange of nutrients and fluid between the plasma and the arterial wall; maintenance
of vascular tone by release of nitric oxide, prostacyclin, endothelin and angiotensin II;
formation and secretion of a series of growth-regulatory molecules and cytokines;
formation and maintenance of connective tissue matrix, including the basement
membrane upon which it lies, collagen and elastic fibres, and proteoglycans; the
capacity to modify substances from the plasma such as lipoproteins that endothelial
cells can oxidise or otherwise modify as they are transported into the artery wall;
provision of a nonthrombogenic surface by the formation of ectoADPase, PGI2, and
heparin sulphate; and provision of anti-coagulant and pro-coagulant properties (Raines
& Ross, 1995).
Alterations in one or more of these functions of the endothelium are important during
the early phase of atherogenesis. One of the earliest changes in the endothelium is seen
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in its permeability, wherein increased amounts of lipoprotein (in hypercholesterolaemic
patients) are transported by the endothelium to localise in the subendothelial space of
the intima (Simionescu et al, 1990). During transcytosis, many of these lipoprotein
particles may be modified by oxidation or glycation by the endothelium (Steinberg,
1991). The formation of oxidised LDL (oxLDL) may in turn have repercussions on the
endothelium because oxLDL may induce expression of genes that cause it to produce
chemotactic molecules, additional cell adhesion and growth regulatory molecules, and
cytokines (Raines & Ross, 1995). In addition, macrophages become engorged with
oxLDLs and lose their scavenging function to become foam cells which give rise to the
characteristic fatty streak of early plaque formation. Endothelial cells have shear
response elements which can also induce changes in gene expression at sites of change
in blood flow (Nagel et al, 1994) and as a result of hypertension (Chobanian, 1989).
The capacity of the endothelium to maintain normal arterial tone represents an
important contribution from these cells via several molecules, including nitric oxide
and prostacyclin. Ironically, the capacity of the endothelium to produce nitric oxide
may also play a role in its capacity to further oxidise LDL to form oxLDL, which may
also result from endothelial lipoxygenases (Chester et al, 1990). Nitric oxide is not
only vasodilatory but also prevents platelet adhesion and aggregation, and leukocyte
adhesion (Radomski et al, 1987). Endothelium-derived vasoconstrictors such as ET
and angiotensin II are also involved in the maintenance of vascular tone. Therefore, the
balance of these vasodilator and vasoconstrictor effects is important in determining the
dimensions of the arterial luminal diameter, and essential in arteries affected by
atherosclerosis in regulating flow to the heart muscle and brain (Shimokawa &
Vanhoutte, 1990; Dzau, 1990).
Demonstrations of endothelial dysfunction in hypercholesterolaemic animals (Andrews
et al, 1987; Cohen et al, 1988; Verbeuren et al, 1986; Shimokawa & Vanhoutte, 1989;
Tomita et al, 1990) and humans (Ludmer et al, 1986; Chowienczyk et al, 1992; Casino
83
et al, 1993) have been attributed to attenuated endothelium-dependent vasodilatation,
and taken to reflect impaired nitric oxide generation. However, this abnormality may
be due to an increased degradation of nitric oxide by superoxide anion or other
oxygen-derived free radicals (Gryglewski et al, 1986; Minor et al, 1990; Miigge et al,
1991), or altered activity of nitric oxide synthase (Mitchell et al, 1990).
Despite the above comments, the means by which hypertension induces lesions of
atherosclerosis is poorly understood. Genetic studies of hypertension in animals have
used a restriction fragment length polymorphism for renin in the Dahl/TR. salt-sensitive
rat, which co-segregates with existing hypertension, suggesting that a genetic locus
linked with this polymorphism is somehow responsible for the hypertension (Dzau,
1990). Both smooth muscle hypertrophy and intimal hyperplasia occur in animal
models of experimentally induced hypertension, as well as in arteries of humans with
hypertension (Owens, 1989). In the rat, these hypertrophic events have been shown to
be due, at least in part, to an increase in ploidy and in the size of the arterial smooth
muscle cells. There seems to be an interrelationship between mechanisms which induce
smooth muscle proliferation and smooth muscle contraction (Raines & Ross, 1995).
Elements of the sympathetic nervous system which are activated in hypertension can
induce vascular wall growth. Angiotensin II is elevated in many hypertensives and can
directly mediate smooth muscle hyperplasia (Schelling et al, 1991; Baker et al, 1992).
Other vasoactive substances such as serotonin, endothelin-1, and thrombin can also
stimulate smooth muscle replication, whereas inhibitors of vasoconstriction, such as
atrial natriuretic peptide may have an opposing effect (Dzau, 1987).
Similar to changes observed in experimentally induced hypercholesterolaemia,
Chobanian (1990) has demonstrated endothelial dysfunction in experimental
hypertension with monocyte adhesion and trasendothelial migration of the adherent
cells. The monocytes become macrophages after they enter the intima even though little
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or no lipid accumulated in them under these conditions. The combined effects of
hyperlipidaemia and hypertension in rabbits can lead to a marked enhancement of the
lesions of atheroslerosis (Ross, 1995). Thus, the common theme of endothelial
dysfunction, inflammation, and a fibroproliferative response recurs in hypertension as
well as hyperlipidaemia.
Patients with essential hypertension and hypercholesterolaemia have impaired
vasodilatation in forearm and coronary vessels following intra-arterial infusion of
acetylcholine (Chapter 1; Section 1.2.7 and 1.4). It is unclear, however, whether
impaired nitric oxide generation in hypertension and hypercholesterolaemia is confined
to skeletal muscle resistance vessels and coronary vessels, and whether the defect is
specific to nitric oxide generation or also affects other mediators such as prostacyclin.
Having described, in the previous chapter, the pharmacological mechanisms of a
non-invasive method for investigating endothelial function, this technique is now
compared with the 'gold standard' intra-arterial method of assessing endothelial
function in hypercholesterolaemic patients. The aim of this chapter is to establish, in
hypercholesterolaemic patients, whether endothelial dysfunction is restricted the
forearm skeletal muscle vessels, or also measurable in the dermal microcirculation.
5.2 METHODS
5.2.1 SUBJECTS
This study compared 10 hypercholesterolaemic patients who were recruited from the
Cardiovascular Risk clinic at the Western General Hospital in Edinburgh, and 10
healthy control subjects recruited by advertisement (Table 5.1). No subject received
vasoactive or non-steroidal anti-inflammatory drugs during the week before each phase
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of the study, and all of the subjects abstained from alcohol for 24 hours, and from
food, caffeine-containing drinks and cigarettes for at least 2 h before each phase.
Subjects rested in the recumbent position during each phase, in a quiet room
maintained at a constant temperature of 22-25°C. All participants gave their written,
witnessed, informed consent to participate in these studies which were approved by the
Lothian Area of Medical Ethics Committee.
5.2.2 ARTERIAL INFUSION AND FOREARM BLOOD FLOW STUDY
This part of the study took place on two separate occasions, separated by 14 days. On
one study day, having acclimatised to an ambient temperature of 24-26°C for 30 min,
basal measurements of forearm blood flow were obtained (methodology described in
Chapter 3; Section 3.2.3; pp 44-45). A pharmaceutical-grade, sterile and pyrogen-free
preparation of acetylcholine (Miochol, IOLAB, Bracknell, UK) was diluted in
physiological (0.9%) saline to give 7.5 and 15 jig ml1 solutions which were each
infused intra-arterially at 1 ml min-1 (Chowienczyk, 1992). The same pharmaceutical
brand of sodium nitroprusside described in Chapter 4 (Section 4.2.2; p 69) for
iontophoresis was used for intra-arterial infusion in the present study. However, its
preparation was different: sodium nitroprusside was reconstituted in physiological
saline and diluted to give 3 and 10 pg ml"1 solutions which were also infused intra-
arterially at 1 ml min-1 (Chowienczyk, 1992).
Acetylcholine and sodium nitroprusside were then infused, in random order, via the
left brachial artery at 1 ml min-1 for 6 min at each dose (Chowienczyk et al, 1992).
Forearm blood flow measurements were obtained during the final 3 min of each dose.
On the second study day, this protocol was repeated 30 min after intravenous bolus
injection of aspirin 600 mg (as in Chapter 4).
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5.2.3 IONTOPHORESIS STUDY
Iontophoresis with acetylcholine and sodium nitroprusside was performed, on the third
day of the study, before and after administration of aspirin (as in Chapter 4).
5.2.4 STATISTICAL ANALYSIS
Data are represented as mean±SEM. Analysis of iontophoretic response curves was by
repeated measures analysis of variance (StatView on Macintosh).
Sample size Age range MAP















ANOVA P=0.07 P=0.32 P=0.0001 P=0.07
TABLE 5.1:
Demographic data from hypercholesterolaemic patients and from age- and sex-matched control subjects.
HC = hypercholesterolaemic patients; MAP = mean arterial blood pressure. Data from both groups
were analysed by repeated measures analysis of variance (ANOVA), and P-values are shown.
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5.3 RESULTS
5.3.1 ARTERIAL INFUSION AND FOREARM BLOOD FLOW STUDY
The increase in forearm blood flow following intra-arterial infusion of acetylcholine
was significantly blunted in hypercholesterolaemic patients compared with healthy
controls (Fig. 5.1). Aspirin had no effect on controls, but restored the vasodilator
response towards normal in hypercholesterolaemic patients (Fig. 5.1). Responses to










Forearm vasodilatation in response to intra-arterial acetylcholine in hypercholesterolaemic patients
(O), expressed as percentage change (%A) from baseline, was significantly lower than the
vasodilatation in control subjects (■) (P=0.0002). Bolus intravenous injection of aspirin (600 mg) did
























Forearm vasodilatation in response to intra-arterial sodium nitroprusside in hypercholesterolaemic
patients (•), expressed as percentage change (%A) from baseline, and in healthy controls (■) before
intravenous injection of aspirin (600 mg). Responses after aspirin injection in patients (O) and in
controls (□) are also shown.
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5.3.2 IONTOPHORESIS
The increase in skin blood flow in response to the iontophoresis of acetylcholine was
similar for both groups before aspirin. However, the inhibitory effect of aspirin on
dermal cholinergic dilatation was greater in the hypercholesterolaemic group (Fig. 5.3)
such that, in the presence of aspirin, cholinergic vasodilatation was markedly impaired
(P=0.0001). Responses to sodium nitroprusside were lower in the patient group, both












Iontophoresis of acetylcholine caused a dose-related increase in skin red cell flux in
hypercholesterolaemic patients (O) and in healthy control subjects (■). After bolus intravenous
injection of aspirin (600 mg), this response was partially inhibited in the controls (□) and more


















Iontophoresis of sodium nitroprusside caused an increase in skin red cell flux in hypercholesterolaemic
patients (O) and in healthy controls (■). Basal responses in hypercholesterolaemic patients were




In keeping with other studies (Chowienczyk et al, 1992; Casino et al, 1993), the
findings of the present study confirm that cholinergic vasodilatation is impaired in
hypercholesterolaemic patients (Fig. 5.1). In the forearm, this defect is partially
reversed by aspirin, suggesting either that a vasoconstrictor prostaglandin influences
tone in this vascular bed in hypercholesterolaemia, or that in the presence of aspirin,
nitric oxide release is improved in hypercholesterolaemia. This partial reversal is
consistent with results in essential (but not secondary) hypertension where the
vasodilator response to acetylcholine is increased in the presence of indomethacin
(Taddei et al, 1993). In addition, this normalisation of the acetylcholine response
following cyclooxygenase inhibition has been seen in spontaneously hypertensive rats
(Iwama et al, 1992), and in stroke-prone spontaneously hypertensive rats (Diederich et
al, 1990). This evidence suggests that the release of relaxing factors may be normal,
but that the concomitant, possibly enhanced, release of a cyclooxygenase-dependent
endothelium-derived contracting factor (probably prostaglandin H2) accounts for the
impaired relaxation. Furthermore, defects in the metabolism of the contracting
prostanoid, PGH2 could not only upregulate its synthesis, but could also inhibit
prostacyclin synthase (Lin et al, 1994). However, there appeared to be no differences
in forearm vasodilatation to sodium nitroprusside between the two groups. Both
sodium nitroprusside and native nitric oxide act by stimulating soluable guanylate
cyclase. Therefore, impaired vasodilation to acetylcholine may have nothing to do with
the amount of nitric oxide generated or reduced smooth muscle responsiveness, and it
may be that the explanation of impaired nitric oxide production usually given to
account for endothelial dysfunction may need to be re-addressed.
Results in dermal vessels were different from those in the forearm.
Hypercholesterolaemic patients did not have impaired cholinergic vasodilatation in
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dermal vessels in the absence of aspirin, possibly because nitric oxide generation is
normal, or is not an important mediator of vasodilatation in the dermis, consistent with
results from the previous chapter. However, the inhibiting effect of aspirin was greater
in these patients so that impaired cholinergic vasodilatation was evident in the presence
of aspirin. This suggests that they have increased generation of dilator prostanoids by
acetylcholine, but decreased generation, or sensitivity to, other mediators.
Responses to sodium nitroprusside in the dermis were also different between healthy
subjects and hypercholesterolaemic subjects. In the forearm, previous investigators
have used sodium nitroprusside as a control to show that changes in cholinergic
vasodilatation are not mediated by altered vascular smooth muscle sensitivity to nitric
oxide. In the present study, sodium nitroprusside sensitivity in the forearm was not
different in hypercholesterolaemia and not affected by aspirin. However, in dermal
vessels, the vasodilatator response to sodium nitroprusside was impaired in
hypercholesterolaemia and unaffected by aspirin. As sodium nitroprusside acts by
stimulating guanylate cyclase to increase cGMP levels, it may be that, in the dermis,
there is a defect in this second messenger system, and therefore, a reduced sensitivity
to nitric oxide, whether endothelium-derived or exogenously-donated. Vasodilatation
mediated by prostanoids such as prostacyclin is cAMP-dependent, and, in dermal
vessels, this pathway may be favoured in hypercholesterolaemia.
Thus, smooth muscle sensitivity to sodium nitroprusside appears only to be reduced in
the dermis, while endothelial dysfunction affects the forearm and the dermis:
vasodilatation to acetylcholine appears to depend on the local balance between
vasoactive prostanoids in these tissues.
In hypertensive animal models (spontaneously hypertensive rats), the sodium
nitroprusside response is enhanced compared with normotensive controls (Wistar-
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Kyoto rats) (Tesfamariam et al, 1988; Diederich et al, 1990), a finding which is more
pronounced after the endothelium has been removed. This may be due to hypertrophy
of the media in spontaneously hypertensive rats leading to increased responsiveness to
sodium nitroprusside, or due to removal of endothelium-derived contracting factors.
Vascular hypertrophy may not be present in dermal microvessels of
hypercholesterolaemic patients, and may explain why there was reduced, rather than
enhanced sensitivity to sodium nitroprusside. In addition, the findings of an impaired
sodium nitroprusside response could account for the impaired cholinergic dilatation in
dermal vessels in hypercholesterolaemia in the presence of aspirin, since dilatation may
then depend on nitric oxide.
The present findings in hypercholesterolaemia suggest that, in contrast with the
forearm circulation, dermal vessels have increased dilator prostanoid generation, and
the impairment of cholinergic vasodilatation in the presence of aspirin can be attributed
to impaired vascular smooth muscle sensitivity to nitric oxide. The 'endothelial
dysfunction' of hypercholesterolaemia may, therefore, be different between certain
vascular beds and certain endothelial mediators. However, in addition to assessing
endothelial function, iontophoresis also provides important information on smooth
muscle function.
Despite the discussion in Section 5.1, the relationship between hypertension and
atherosclerosis and its clinical complications is poorly understood. Further study is
needed of the mechanisms by which hypertension itself and in combination with other
risk factors affects the arterial wall. Whether structural or functional abnormalities of
the vessel wall themselves contribute to the development of hypertension is the subject









Established essential hypertension is characterised by increased peripheral vascular
resistance, reflected predominately in vessels with an internal diameter of <100 qm
(Struijker Boudier et al, 1992). This may be due to structural abnormalities, such as
reduced luminal diameter, or a reduction in the density of vessels per unit volume of
tissue (rarefaction), or functional abnormalities or a combination of both. However,
from studies in established hypertension, it is not possible to ascertain whether
vascular abnormalities are a cause or consequence of the rise in blood pressure.
Hypertension has been defined by the World Health Organisation criteria to be present
if systolic blood pressure (SBP) is 140 mm Hg or more and/or diastolic blood pressure
(DBP) is 95 mm Hg or more. As such, it has been shown to affect up to 24% of all
individuals from populations within developed societies, and up to 50% of people over
fifty years of age (Burt et al, 1995). The cardiovascular, cerebrovascular and renal
complications of hypertension exert a significant impact on health care resources. A
recent survey has shown that only 53% of all hypertensives are on treatment for
hypertension in order to prevent secondary complications (Burt et al, 1995). Despite
this, hypertension remains the commonest reason for initiating life-time medication
(Rose, 1985). In 95% of cases, hypertension is a primary condition labelled as
essential hypertension, on the basis that no underlying or secondary causes for the
elevation in blood pressure (BP) such as renal artery stenosis, hyperaldosteronism or
phaeochromocytoma have been diagnosed (Berglund, 1985). However, the causes of
elevated BP in essential hypertension remain unclear.
Hypertension does not have a defined phenotype, but is simply the tail of a skewed
frequency-distribution curve for blood pressure (Pickering, 1968). The distribution of
measured BP among individuals from a population is a consequence of their biological
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diversity, their adopted lifestyle and errors or variation in the measurement. Various
arbitrary values have been used to define hypertension of differing severities in the
clinical setting, but measured blood pressure has been shown both to increase with age
and be influenced by situational effects at the time ofmeasurement. Assessments of the
distribution of blood pressure within populations have often been based on single
measurements thereby potentially over-estimating the true prevalence of essential
hypertension (Pickering, 1961). In early studies, complications such as heart failure,
impaired renal function or retinopathy were often labelled as a complex of symptoms
equating with 'hypertension' and subsequently included in the analysis of some
populations, leading to falsely high estimates (Pickering, 1961; Murphy et al, 1967).
Familial co-segregation of high blood pressure and its complications is well-
documented (Miall et al, 1963; Ward, 1990), and could be a consequence of common
environmental, genetic or combined factors. In addition, it could be due to the
influences of age, sex and other confounding genetic or environmental factors such as
obesity. These might not be randomly distributed through affected families, potentially
introducing bias. Many early studies of 'essential' hypertension should also be
interpreted with caution. The medical technology of today was not available to early
investigators, and reports of quite severe hypertension in children (Ayman, 1934)
suggests that secondary causes may not have been adequately excluded from the
groups studied.
Between populations, blood pressure differences appear to be influenced more by
environmental and socio-cultural factors, in particular, dietary sodium intake, physical
activity, obesity and psychosocial stress (Ward, 1990). Though genetic factors may
play a role, for example by influencing sodium handling (Oshima et al, 1994) or the
degree of obesity, 'Westernisation' of lifestyle is likely to be a major factor. However,
within groups from diverse ethnic and genetic backgrounds, the presence of familial
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co-segregation has prompted investigators to look at genetic causes. Piatt (1947) found
an excess of hypertension in parents of hypertensive probands, compared to the
parents of normotensives, but relied on histories suggestive of hypertension-related
complications (Piatt, 1947). Reported transmission of high blood pressure through
three generations (Ayman, 1934), together with an apparent partition in the frequency-
distribution curve for blood pressure measurements from siblings of hypertensive
patients giving a bimodal curve with approximately equivalent portions, prompted him
to suggest that blood pressure was inherited in a single autosomal dominant gene
(Piatt, 1947 and 1959). However, Murphy (1964) showed that apparent bimodality or
polymodality could arise from a number of errors, including observer differences, digit
preference in blood pressure recording (i.e., selecting against intermediate values), the
class intervals used in presenting the data, and small sample sizes, even when taken
from a population with a unimodal distribution.
From a larger number of subjects in the Precursors of Hypertension and Coronary
Disease Study, coordinated by John Hopkins University, both SBP and DBP were
shown to have distributions with a positive skew which could be restored to a binomial
distribution following logarithmic transformation (Murphy et al, 1967). Hamilton and
colleagues (1954) recognised the need for adjustment of BP for age and sex, and
found no natural dividing line between hypertensives and normotensives (Hamilton et
al, 1954a, and 1954b). They did, however, find a consistent familial co-segregation,
with regression coefficient for SBP and DBP of 0.22 and 0.18 respectively,
irrespective of whether the probands were normotensive or hypertensive (Hamilton et
al, 1954c). In a larger population-based study which took a random sample from the
general population, in Rhondda Fach, UK, it was estimated that 33% of SBP and 20%
of DBP was genetically determined. No suggestion of bimodality was seen for BP, but
it was accepted by the authors that single gene inheritance could account for a very
small number of cases (Miall, 1963).Other population-based studies including the
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Tecumseh (Deutscher et al, 1966) and Framingham (Castelli et al, 1986) studies in the
USA have found variable but significant regression coefficients for first degree
relatives of hypertensive probands.
If genetic factors are important in the aetiology of essential hypertension, they
potentially could be operating before the clinical diagnosis is made, hence it has been
of interest to ascertain whether familial co-segregation of BP existed from childhood.
A study performed in children aged 2-14 years from 192 families demonstrated familial
co-segregation of BP (Zinner et al, 1971). This was achieved by observing that the
distribution ofmean familial scores (in standard deviation units (SDU) where one SDU
is equal to the individual's BP minus the mean for their specific age- and sex-group
divided by the SD of mean BP in that group) differed significantly from the expected
normal distribution (which would have an SD of one, and a mean of zero). Stronger
regression coefficients existed between child propositi and their siblings compared
with their mothers. A weak correlation between infant and maternal BP has been found
at birth, but a significant relationship with paternal BP was not found until one month
old (Zinner et al, 1985). At birth, infant BP could be affected by the intrauterine
environment which in turn may be influenced by both maternal genes and
environment. A significant contribution to any expected correlation in BP between
parents and offspring and between offspring could be a consequence of shared
environment. In the case of DBP, 67% of the expected correlation was calculated to be
due to environment, and 33% due to shared genes (Annest et al, 1979).
Pickering and Piatt became engaged in a highly publicised debate over the inheritance
of essential hypertension, but Pickering has gained more support for his proposal of a
polygenic inheritance together with an environmental influence as the basis for the
disease (Pickering, 1961 and 1968; Piatt, 1947 and 1959; Miall, 1963; Williams et al,
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1992). It has now been estimated that between 20-60% of the population variability in
BP is genetically determined (Ward, 1990; Soubrier, 1993).
Recently, clear examples of autosomal dominant inheritance of hypertension mediated
by single gene defects have been described. Glucocorticoid-remediable
hyperaldosteronism (GRA) does not reliably have hypokalaemia but it always presents
early in life with a positive family history of low renin to allow distinction from
essential hypertension. With this in mind, diagnosis of GRA rests on finding elevated
urinary excretion of steroid metabolites, 18-hydroxycortisol and 18-oxycortisol. Lifton
and colleagues identified linkage of GRA with a restriction fragment length
polymorphism arising from a fusion event occurring between the ACTH responsive
regulatory sequences of the 118-hydroxylase gene and the coding sequences of the
aldosterone synthase gene. This has resulted in ectopic expression of aldosterone
synthase in the adrenal zona fasciculata which responds to stimulation by ACTH rather
than angiotensin II or potassium (Lifton et al, 1992).
Liddle's Syndrome (pseudoaldosteronism) has long been recognised as having an
autosomal dominant mode of inheritance with constitutive activation of the Na+-H+
exchange channel in the distal tubule (Botero-Velez et al, 1994). Recently,
polymorphisms for the gene coding for the B-subunit of the epithelial Na+-channel have
been found to be linked with hypertension in five kindreds with the syndrome
(Shimkets et al, 1994). It is, therefore, quite possible that other single gene defects
may be identified causing hypertension in certain kindred (Kurtz, 1993).
Other candidate genes have included one for electrolyte metabolism, e.g., for sodium-
lithium countertransport (Hasstedt et al, 1988) and urinary kallikrein (Berry et al,
1989), and the glucocorticoid receptor gene (Watt et al, 1992). However, polygenic
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and environmental causes are also considered important, and it is likely that
hypertension results from an overlap of all of these factors.
High blood pressure in humans may result from the interaction of a number of genes -
with each other and with the environment (Lindpainter, 1993). The genetic
heterogeneity of the human race and the difficulty in controlling environmental factors
makes genetic investigation problematic. Recent work by Barker (1989, 1990, 1992
and 1995), approaches the 'initiation' of hypertension from a different perspective,
suggesting a fetal origin for this and other cardiovascular diseases.
Barker and colleagues suggest that the origins of adult hypertension are initiated before
childhood, i.e., during fetal growth (Barker et al, 1990; Barker, 1992). The
hypothesis states that fetal undernutrition in middle to late gestation 'programmes' later
development of coronary heart disease, hypertension and diabetes (Barker, 1992).
Low birth weight and a disproportionate placental weight, head size, and length are
markers of lack of nutrients or oxygen at critical stages of fetal development. This
programming causes permanent alterations in structure, physiology and metabolism of
affected individuals. Earlier this century, geographical patterns of poor maternal health
and physique, poor fetal growth, and high death rates from cardiovascular disease
have been derived from maternal and infant mortality data (HMSO, 1910; Campbell et
al, 1932). The first evidence of an association between birth weight and adult
cardiovascular disease came from the 'Hertfordshire' retrospective study, in which
5654 men, bom between 1911-30, were studied. Those who had the lowest weights at
birth and at year 1, subsequently had the highest death rates from ischaemic heart
disease (Barker et al, 1989). In following up adults who were bom between 1935-43
in a hospital in Preston which kept detailed, standardised records of births, Barker
gained the evidence which confirmed his 'programming' hypothesis (Barker et al,
1990). These observations support Folkow's proposal that adult hypertension is
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determined by initiating and amplification mechanisms (Folkow, 1978). Furthermore,
the theories of Barker are supported by increasing evidence from other workers
(Edwards et al, 1993; McKeigue et al, 1994; Fall et al, 1995), and have prompted a
part of the study described later in this chapter.
6.1.1 Vascular abnormalities in essential hypertension:
cause or consequence?
Ascertaining whether vascular functional and/or structural abnormalities are a cause or
consequence of essential hypertension does not require the use of molecular genetics,
but of a novel epidemiological model. In epidemiological studies of high blood
pressure, it has often been difficult to identify familial predisposition in groups of
young people with and without a family history, because of a lack of parental blood
pressure data (Watt, 1986; Ward, 1990). In some studies, a family history has been
determined on the basis of information supplied by subjects at interview rather than on
the basis of data from both parents (Orchard et al, 1982; Sigurdsson et al, 1983). The
Tecumseh study (Deutscher et al, 1966), however, showed that the proportion of
offspring in the top 20% of their age- and sex-specific blood pressure distribution is
greatest when both parents are in the top 20% and least when both parents are in the
bottom 20%. The same pattern was observed in relation to offspring in the lowest 20%
of their blood pressure distribution. This high/high; low/low approach was used in a
study in South Wales (Watt et al, 1983), but comparison of individuals with and
without a family history provides a minimal contrast in predisposition (Watt, 1986).
Thus, even in the Tecumseh and South Wales studies, subjects from both the
high/high and the low/low groups showed a wide range of blood pressure levels, with
only a general tendency towards high and low blood pressure respectively (Watt et al,
1992). This led Watt et al (1992) to devise a novel epidemiological model (described
below) providing contrasting predisposition to high blood pressure.
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In 1977, during the screening programme for the MRC Mild Hypertension Trial, blood
pressure was measured in 603 couples at the Ladywell Medical Centre. In 1985, blood
pressure was measured in 864 of their offspring (aged 16-24 years). The object was to
define groups with contrasting predisposition to high [H] or low [L] blood pressure,
and to define further whether the predisposition was familial [F] or non-familial [NF],
Offspring blood pressure was plotted against mean parental blood pressure using age-
adjusted Z-scores (Figure 6.1). To get at least 50 in each group, parental and offspring
Z-scores both outwith 0.3 SD of the mean were chosen to define the 'four corners'.
Offspring, therefore, had either a predisposition to high blood pressure which was
non-familial [HNF]; a predisposition to high blood pressure which was familial [HF];
a predisposition to low blood pressure which was familial [LF]; or a predisposition to
low blood pressure which was non-familial [LNF]. In this model, therefore, subjects
are identified as having either a high or low risk of developing hypertension on the
basis of their blood pressure in early adulthood, and are further classified as to whether
the risk is familial or sporadic on the basis of both their parents' blood pressure.
Factors which are associated with higher blood pressure in the offspring irrespective of
parental blood pressure are likely to be secondary to high blood pressure and would be
seen in HNF and HF offspring vs. LNF and LF offspring. Factors which are
associated with high blood pressure would be seen only in those offspring whose
parents' blood pressure is high, and are themselves likely to explain the familial
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The Ladywell 4 corners model of contrasting predisposition to high blood pressure (see text). For
clarity, only a sample (approximately 25%) of the 864 data-points are shown.
This model has previously been used to investigate abnormalities of glucocorticoid
metabolism and the renin-angiotensin system (Watt et al, 1992). Offspring with a
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predisposition to high blood pressure were found to have elevated plasma
angiotensinogen, angiotensin converting enzyme and angiotensin II levels, and
increased circulating levels of Cortisol and 18-OH corticosterone, only when the
predisposition was familial [HF]. This group also had raised atrial natriuretic peptide
levels, but this was not statistically significant. In addition, 27% of this group were
homozygous for the larger allele of the restriction fragment length polymorphism
identified by the glucocorticoid receptor gene probe, compared with 9% of offspring
who had a familial predisposition to low blood pressure [LF],
Despite findings of linkage between the angiotensin converting enzyme gene in
spontaneously hypertensive rats (Iwai & Inagami, 1992), no such linkage was found
in humans in another previous phase of this study (Harrap et al, 1993). Also, the Sa
gene (Harrap et al, 1995) was found not to influence the renal characteristics
(variations in electrolyte metabolism and the renin-angiotensin system) that may
contribute to the development of hypertension.
6.1.2 The present study
In Chapter 1, the concept of vascular functional and structural defects contributing to
hypertension was introduced. Chapters 2-4 were concerned mainly with the functional
importance of blood vessels in healthy subjects, particularly in relation to the vascular
endothelium which produces mediators influencing blood vessel tone. In the previous
chapter, the investigation included patients with established hypercholesterolaemia and
differences between forearm resistance vessels and dermal microvessels were
observed. In this chapter, attention is focused on whether functional or structural
abnormalities are a cause or consequence of essential hypertension. Iontophoresis of
acetylcholine and sodium nitroprusside, as described previously, was performed as a
method of assessing endothelial function in the group. In addition, urinary and plasma
nitrate levels were estimated as an indication of nitric oxide production (Green et al,
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1982). In essential hypertension, the characteristic increase in peripheral vascular
resistance may reflect structural as well as functional changes in these blood vessels
(Chapter 1), thus, the structure of microvessels was also investigated.
6.2 METHODS
6.2.1 SUBJECTS
The study described in this chapter was conducted between March 1993 and December
1994.105 male offspring drawn at random from each of the 4 corners were recruited.
Details of the subjects are shown in Table 6.1. The author did not know from which
corner subjects were drawn until data collection and analysis was complete (the 'code'
was held by Professor Graham Watt, Department of General Practice, University of
Glasgow). No subject was taking relevant regular medication. Subjects gave written,
witnessed, informed consent. Approval was obtained from the Lothian Ethics of
Medical Research Committee.
6.2.2 EXPERIMENTAL PROTOCOL
After an overnight fast from 2200 h, abstention from alcohol and caffeine for 12 hours
and from proprietary drugs including aspirin for 10 days, subjects attended the clinical
laboratory at 0900 h, bringing with them a 24-hour urine collection, which they had
started the morning before the study. Height and weight were recorded before subjects
lay supine and acclimatised to a controlled environmental temperature of 22-25°C for
>40 minutes, during which baseline recordings of blood pressure and cardiac function
were made. Blood was then taken for biochemical and nitrate level determination. The
following measurements were then made in sequence. In the right arm, maximum
vasodilatation of skin microvessels in response to local heating to 42°C followed by a
period of ischaemia was measured by laser Doppler fluximetry. In the left arm, nailfold
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capillary blood velocity, red cell column width and capillary numbers on the dorsum of
the ring finger were measured by intravital videomicroscopy (as discussed in Chapter 3
Section 3.2.4; pp 46-47). Iontophoresis of acetylcholine and sodium nitroprusside was
performed in the volar surface of the right arm (Chapter 4; Section 4.2.2; pp 65-67 and
68-69). Blood flow was measured in the right forearm before and after ischaemia,
using strain gauge plethysmography (Chapter 3; Section 3.2.3; pp 44-45). The
protocol was completed by 1130 h.
6.2.3 BLOOD PRESSURE AND CARDIAC FUNCTION
Blood pressure was recorded 4 times at 5-minute intervals using the Hawksley
random-zero sphygmomanometer (Wright & Dore, 1970) as in earlier phases of the
study. Because of the recent controversy over this device (Conroy et al, 1993), for
calculations of vascular resistance these measurements were repeated using a semi-
automated machine (Takeda UA 751 sphygmomanometer) which has been
independently validated (Wiinberg et al, 1988; Evans et al, 1989). The mean of the last
three recordings was used in subsequent analyses. Mean arterial pressure was
calculated using the formula given in Chapter 2 (Section 2.2.3; p 32). Measurements
of cardiac output and stroke volume were made during the final 20 min of the
acclimatisation period, using a non-invasive bioimpedance method (BoMed NCCOM3;
Chapter 2; Section 2.2.3; p 32). Results were divided by body surface area to give
cardiac index and stroke index respectively. Peripheral vascular resistance was
calculated as (mean arterial pressure with Takeda instrumentMcardiac index).
6.2.4 IONTOPHORESIS
Iontophoresis of acetylcholine and sodium nitroprusside was performed as described
in Chapter 4 (Section 4.2.2). In the present study, acetylcholine, sodium nitroprusside
and vehicle were iontophoresed in the right arm in random order.
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6.2.5 PLASMA AND URINARY NITRATE LEVELS
A fasting blood sample was taken from each subject at the end of the acclimatisation
period. 10 ml was collected in a lithium-heparin tube and centrifuged at 3000 G for
10 min. Plasma was then pipetted into a plain tube and stored at -80°C until all samples
were available for analysis. The urine volume was measured, and the aliquoted into
smaller containers for future analysis.
Using the method of Green et al (1982), plasma and urine samples (each of 2.5 ml)
were defrosted at room temperature for 2 hours. In brief, 0.5 ml from each plasma
sample, was pipetted into an Eppendorf microcentrifugation tube, to which 0.1 ml of
35% sulphosalacylic acid (Sigma-Aldrich Company Ltd., Poole, Dorset, UK) was
added to deproteinise the sample. Each mixture was vortexed for 10 s every 5 min for
30 min at room temperature, using a bench-top agitator (Fison's WhirliMixer, Fison's
Ltd., Loughborough, UK), and centrifuged in a bench-top centrifuge (Camlab
Microcentrifuge 154; Camlab Ltd., Cambridge, UK) at 13 000 G for 5 min. The
supernatant (0.2 ml) was transferred to a fresh Eppendorf tube and neutralised by
adding 0.06 ml 5% sodium hydroxide in 0.3 ml 5% NH4C1 mobile phase buffer.
Urine samples did not require deproteinisation, and were diluted 10 fold in buffer
before being injected into the spectrophotometer.
Each sample of 50 fi.1 was injected, using a glass syringe (SGE Series n, Crawford
Scientific Ltd.), via an infusion pump (P100 Isocratic Pump; Spectra Physics,
Thomson Scientific Ltd., Oxford, UK), into a u.v./visible spectrophotometer (Spectra
Series UV100; Spectra Physics). The nitrate in each sample was reduced to nitrite by
cadmium in the column. Nitrite reacts with Griess reagent in the column to form a dye,
and its absorbance was detected at 546 nm. The spectrophotometer was connected to
an Apple Macintosh microcomputer via a digital converter (MacLab; Chapter 3; Section
108
3.2.4; p 45). Data were stored in a Chart program (Chapter 3; Section 3.2.4; p 45) for
subsequent analysis.
6.2.6 DERMAL VASODILATATION
Increases in dermal blood flow were estimated by laser Doppler fluximetry (Chapter 3;
Section 3.2.4; p 48) in response to two stimuli. One of these local heating of the skin;
the other, ischaemia induced by inflation of an upper arm cuff to 220 mmHg.
(i) Local heating of skin
The right forearm was pre-heated to 36°C using a hairdryer, and a brass skin warmer
1 cm in diameter (Skin Temperature Controller, Moor Instruments Ltd., Axminster,
Devon, UK) was attached to the volar surface using a double-sided adhesive disc
(Rayman et al, 1986). A thermocouple wire was positioned through a fine channel
offset from the centre of the skin warmer and temperature was recorded using a Fluke
52 K/J digital thermometer. The skin was heated to 42°C for 30 min, after which the
thermocouple was removed and replaced with a laser Doppler probe so that flux could
be recorded for 30 s. The channel could be rotated so that flux was averaged from 8
different sites.
(ii) Post-ischaemic hyperaemia
Immediately after heating, an upper arm cuff was inflated to 220 mm Hg for 5 min and
flux was measured at the same site for 30 s after releasing the cuff. The mean flux
during these 30 s was used for further analysis.
6.2.7 CAPILLAROSCOPY
(i) Capillary blood velocity
Capillaries were visualised using a single television videomicroscopy system as
described in Chapter 3 (Section 3.2.4; pp 46-47). The television camera was connected
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both to a microscope and to a video cassette recorder so that images could be recorded
for subsequent analysis.
To analyse at least six capillary loops, 4-6 different microscopy fields selected from
across the nailfold were each recorded for 2.5 minutes. In some subjects it is
impossible to visualise as many as six capillary loops due to damage or injury to the
skin (e.g., in manual workers or nail-biters). These subjects were excluded from
further analysis, so that studies were completed for 20 HNF; 22 HF; 21 LF; and 20
LNF subjects. For these subjects, capillary blood velocity was measured in the arterial
limb of six capillaries by off-line analysis of the video recordings using computerised
photometric temporal correlation (Chapter 3; Section 3.2.4). Capillary blood velocity is
variable from one capillary to the next within the same individual and, in the present
study, gave an intra-subject coefficient of variation (CV) of 31+2%. However, as the
mean of six capillaries was taken from each individual, the inter-subject variability was
only 12.3±1%.
(ii) Red cell column width
Red cell column width was measured at 3 sites on the arteriolar limb of each of the six
capillaries using computerised window splitting (Fagrell et al, 1994). Red cell column
width is a surrogate measure of luminal diameter if it is assumed that the width of the
plasma layer at the circumference of the red cell column remains constant between
groups. The CV for red cell column width was 14±1%
(iii) Capillary numbers
To measure capillary numbers, the summits of capillary loops were visualised 'end-on'
in the dermis of the dorsum of the 2nd phalanx of the left ring finger. Perfused
capillaries (i.e., those in which moving erythrocytes were seen) were counted in 60
second recordings from each of 6 fields of 0.5 x 0.5 mm (calibrated with a graticule
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micrometer) both before and during venous occlusion with a digital cuff connected to a
mercury sphygmomanometer and inflated to 40 mm Hg for 10 min. This technique
was successful in all study participants. Intra-subject coefficents of variation between
the six recordings were 8±1% for basal capillary number and 7+1% for capillary
number during venous occlusion.
6.2.8 FOREARM BLOOD FLOW AND VASCULAR RESISTANCE
Forearm blood flow was measured using venous occlusion plethysmography with
temperature-compensated indium/gallium in silastic strain gauges calibrated on the
limb, as previously described (Chapter 3; Section 3.2.3; pp 44-45). In brief, during 3
min recording periods a wrist cuff was inflated to 220 mmHg to exclude the hand
circulation and flows were measured for 10 s in every 15 s by repeated inflation of an
upper arm congesting cuff to 40 mmHg. After basal recordings, the upper arm cuff
was inflated to 220 mmHg for 12 min and recordings were made for the first 60 s after
release of the cuff, i.e., during the maximum reactive hyperaemic period (Patterson,
1955; Pedrinelli et al, 1990). The slopes of the final 5 recordings from each period
were averaged to determine flow, and minimum vascular resistance was calculated as
(mean arterial pressure with Takeda instrument)+(forearm blood flow).
6.2.9 BIRTH WEIGHT
Subjects were asked to establish their mothers' recall of their birth weight and to bring
details when attending the study.
6.2.10 STATISTICAL ANALYSIS
Results are mean ± SEM. Comparisons across the 4 comers were by factorial analysis
of variance, followed by comparison of comers by Fisher's probability of least
squares difference test when P values for the analysis of variance were <0.05.
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When a difference was observed between HNF and HF offspring, there was a
possibility that it related to the small difference in blood pressure between these two
groups, which has developed since the study was established. Therefore, multiple
regression analyses were performed with controlling variables of mean arterial
pressure (using the Hawksley) and comer allocation (either HNF or HF assigned
values of 0 and 1).
When no significant difference was observed in the analysis of variance, 95%
confidence intervals of the observed differences between HF and LF offspring were
calculated from an unpaired two-tail Student's t test. These comers were chosen since
they contain subjects with the greatest contrast in their predisposition to high blood
pressure.
6.3 RESULTS
6.3.1 BLOOD PRESSURE AND CARDIAC FUNCTION
See Table 6.1. Blood pressures were higher, as expected, in HNF and HF than in LF
and LNF offspring. In addition, blood pressures were significantly higher in HF than
in HNF offspring. Pulse rate was higher in comers HNF and HF than in LF and LNF.
Cardiac index, stroke index, and total peripheral vascular resistance were not
significantly different between comers. However, the 95% confidence intervals of the
differences were wide for cardiac index, for which there was a trend towards higher
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4.3±0.2 4.5±0.2 4.0±0.12 3.9±0.2 P=0.10
Stroke index
(1 min"1 m"2)
65±3 65±3 67±2 64±3 P=0.87
Peripheral vascular resistance
index
(dyn min cm"5 m"2)
2L5±1.1 21.8±1.2 20.8±0.6 22.2±1.0 P=0.77
Basal forearm vascular
resistance
(mmHg ml"1 min 100 ml)
Minimal forearm vascular
resistance


































Demographic, haemodynamic, and capillaroscopy data for subjects from the four comers of the study,
t when P<0.05 for analysis of variance, subsequent comparisons between comers refer to P<0.05 for
Fisher's two-group probability of least squares difference test.
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6.3.2 IONTOPHORESIS
Responses to sodium nitroprusside were higher in HF and LNF offspring than in
HNF and LF offspring (Fig. 6.2). Responses to acetylcholine, however, were not
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FIGURE 6.2:
Dose response to transdermal iontophoresis of sodium nitroprusside across the 'four comers': HNF:
high offspring/low parents (•); HF: high offspring/high parents (□); LF: low offspring/low parents
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FIGURE 6.3:
Dose response to transdermal iontophoresis of acetylcholine for each of the four comers: HNF: high
offspring/low parents (•); HF: high offspring/high parents (□); LF: low offspring/low parents (O);
and LNF: low offspring/high parents (■).
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6.3.3 PLASMA AND URINARY NITRATE LEVELS
Nitrate measurements were taken as an index of nitric oxide production across the four
comers. There were no significant differences in plasma nitrate levels or in daily rates
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FIGURE 6.4:
Plasma nitrate levels (lower graph) and daily nitrate excretion rate (upper graph) were not significantly




Increase in flux after both local heating and ischaemia was reduced in the same pattern
as capillary number, i.e., lower in HF than in all other offspring (Figure 6.5). The
differences between HNF and HF offspring cannot be accounted for by the
differences in blood pressure alone, since in multiple regression analyses the response
to heating and ischaemia were influenced by corner allocation (PcO.OOOl for both
responses) but not by mean arterial pressure (P>0.6 for both).
o
o
Offspring BP High High Low Low
Parental BP Low High Low High
Corner HNF HF LF LNF
FIGURE 6.5:
Dermal vasodilatation in response to heat and ischaemia in subjects from the four comers. Increasing
flux was measured after heating to 42°C (white bars) and after 5 minutes ischaemia (black bars). Error
bars are mean ± SEM. Analysis of variance for the four comers was significant to P<0.0001 for both
variables, and P values shown refer to subsequent comparison of HNF, LF and LNF offspring with
HF offspring by Fisher's probability of least squares difference test.
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6.3.5 CAPILLAROSCOPY
(i) Capillary blood velocity
There were no differences between corners for capillary blood velocity (Table 6.1).
However, 95% confidence intervals of the differences were wide for capillary blood
velocity, for which there was a trend towards lower values in HF offspring.
(ii) Red cell column width
Luminal diameter, as judged by red cell column width, was not different between the 4
comers (Table 6.1).
(iii) Capillary numbers
Capillary numbers were not different between comers in the basal state, but during
venous occlusion they were markedly lower in offspring with high BP only when
parental BP was high (P<0.003), i.e., lower in HF compared with all other comers
(Figure 6.6). The difference between HNF and HF offspring cannot be accounted for
by the differences in blood pressure alone, since in a multiple regression analysis the
capillary number after venous occlusion was influenced to a greater degree by comer




























Capillary numbers in subjects from tbe four comers. Capillary numbers were measured in the basal
state (white bars) and during venous occlusion (black bars). Error bars are SEM. Analysis of variance
for the four comers was significant to P<0.003 for capillary numbers during venous occlusion, and P
values shown refer to subsequent comparison of HNF, LF and LNF offspring with HF offspring by
Fisher's probability of least squares difference test.
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6.3.6 FOREARM BLOOD FLOW AND VASCULAR RESISTANCE
There were no differences between comers in forearm vascular resistance either in the
basal state or after ischaemia (Table 6.1).
6.3.7 BIRTH WEIGHT
The trend was towards lower birth weight in subjects with high blood pressure if they
had a familial predisposition (HF offspring). However, this difference was not
statistically significant (Table 6.1). Further, it can be seen from these results that LNF
offspring had comparably low birth weights.
6.4 DISCUSSION
The 'four-comers' epidemiological design is a novel attempt to overcome the
difficulties of identifying 'pre-hypertensive' humans in order to explore the primary
mechanisms of their high blood pressure without observing secondary effects of high
blood pressure. The model has been discussed in greater detail elsewhere (Watt et al,
1992). From the present blood pressure levels, the predictions from the original
allocations of offspring to different comers in 1985 are proving to be remarkably
robust. In 1987, when 170 subjects from the four comers last had blood pressure
recorded, mean arterial pressure was 89 mm Hg in HF; 89 mm Hg in HNF; 81 mm
Hg in LF; and 82 mm Hg in LNF offspring (Watt et al, 1992). By comparison with
measurements 7-9 years later (Table 6.1), the contrast in blood pressure between the
comers is increasing with time. Blood pressure has increased most in individuals with
high blood pressure whose parental blood pressure was also high [HF]. These
observations confirm that blood pressure 'tracks' with age (Lever & Harrap, 1992)
and suggest that the combination of parental and offspring blood pressures, rather than
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either alone, provides a more accurate prediction of the subsequent development of
essential hypertension.
However, the fact that blood pressure is now higher in HF than in HNF offspring,
means that the use of HNF subjects as a 'control' group with matched blood pressure
is no longer straightforward. To exclude the possibility that a difference between HNF
and HF offspring is due to the difference in blood pressure alone, where differences
between these corners were observed, multiple regression analyses were performed.
These confirmed that the differences were attributable to corner allocation rather than
blood pressure differences alone. The magnitude of the difference between HF
offspring and the other groups is greater than has been observed between essential
hypertensive patients and controls. Furthermore, for all variables measured, there is no
difference between the other 'high' group [HNF] and the 'low' groups [LF and LNF].
The functional abnormality, in dermal vessels, of reduced maximum vasodilatation,
i.e., increased resistance, is likely to be, at least in part, related to structural rarefaction
observed (see later), rather than to impaired function alone. No significant differences
in endothelial function between the comers, as assessed by transdermal drag
iontophoresis, were observed. The subjects with high blood pressure with a familial
predisposition (HF) did not have an impaired iontophoretic response to acetylcholine.
From previous results for iontophoresis (Chapter 4), the mechanism for dermal
cholinergic vasodilatation appears to be mediated by a prostanoid vasodilator -
probably prostacyclin (PGI2), as the response is markedly attenuated by aspirin, but
not by L-NMMA. In the present study, only basal responses to acetylcholine and
sodium nitroprusside were measured, since manipulation by pharmacological tools
would have affected other microvascular measurements. Therefore, the nature of the
present study may have masked any significant differences. Furthermore, there were
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limits to the nature and number of investigations which could be undertaken in subjects
from this unique population in a single 3-hour study.
The results for iontophoresis of sodium nitroprusside are even more difficult to
explain. In the previous chapter, I demonstrated that hypercholesterolaemic patients
with impaired nitric oxide generation in forearm skeletal resistance vessels had reduced
vascular smooth muscle sensitivity in dermal vessels. No such reduction in sensitivity
was observed in subjects predisposed to high blood pressure. On the contrary,
offspring a familial predisposition to low blood pressure [LF], had the lowest response
to sodium nitroprusside. Further, the 4 corners appear to have separate response
curves, with the closest match observed between HF and LF offspring - the two
opposite extremes in this model of contrasting predisposition! As none of the subjects
studied had a clinical diagnosis of essential hypertension, it may be that iontophoresis
can only detect functional abnormalities in established disease.
HF subjects tended to have the lowest levels of plasma nitrate (no differences were
seen for urinary nitrate levels), which were assayed as an index of nitric oxide
production. Although not statistically significant (P>0.05), this trend was more
convincing than the acetylcholine test (above) for prostanoid-mediated vasodilation.
The result for nitrate levels may have been more clear, had subjects been controlled for
diet which strongly influences nitrate and nitrite levels in urine and plasma.
Furthermore, the assay is not specifically an index of oxidation of endothelium-derived
nitric oxide to nitrate, as nitric oxide may originate in a variety of tissues (Chapter 1).
Nevertheless, it is tempting to speculate that abnormalities of nitric oxide generation
may be present in subjects with high blood pressure who have a familial
predisposition.
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In the present study, this unique population was used to help to distinguish
abnormalities of microvascular function and structure which are likely to be primary in
the development of high blood pressure from those which are secondary to high blood
pressure. A pattern consistent with a primary abnormality for reduced capillary number
(rarefaction) was observed. In addition, there was a substantial impairment in dermal
vasodilatation to heating and to ischaemia (i.e., abnormal in offspring with high blood
pressure only when parental pressure was high [HF>LF], and abnormal in families
with higher blood pressure only when offspring blood pressure was high [HF>LNF]).
There was also a trend towards lower capillary blood velocity in HF offspring.
However, there were no differences in capillary luminal diameter.
The expected haemodynamic impact of microvascular rarefaction is controversial, and
will differ greatly between vascular beds according to the extent of inter-arteriolar and
arteriolar-venular anastomoses. However, calculations by computer modelling of in
vivo beds predict an exponential relationship between vessel number and vascular
resistance (Hudetz et al, 1993). For example, loss of 42% of third-order arterioles in
hamster cheek pouch would increase vascular resistance by 21% (Greene et al, 1989).
In the present study, I have observed a 14% difference in capillary number during
venous occlusion in subjects with a familial predisposition to high blood pressure (Fig.
6.6) which compares with 17% rarefaction in established hypertension (Williams et al,
1990). This was associated with a marked increase in minimum dermal vascular
resistance (Table 6.1), and may have been due to an absence of vessels rather than to
increased walklumen ratio, the hallmark of structural change in larger vessels. In
forearm resistance vessels, vascular resistance and minimum vascular resistance are
increased in patients with essential hypertension (Folkow et al, 1958; Pedrinelli et al,
1990) and in their normotensive relatives (Takeshita et al, 1982). However, I found no
difference between groups in total peripheral or minimum forearm vascular resistance,
which is determined mainly by resistance in skeletal muscle. This raises the possibility
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that microvascular abnormalities associated with a familial predisposition to
hypertension are limited to specific vascular beds, for example affecting dermal but not
forearm skeletal vessels.
Arterioles with luminal diameter 20-400 (im have previously been demonstrated to
have reduced luminal diameter in established hypertension due to vascular hyperplasia
and/or remodelling (Folkow, 1990; Heagerty et al, 1993; Shore & Tooke, 1994).
Increased minimum vascular resistance is considered the hallmark of this structural
change in vivo. The present data suggest that such luminal narrowing as occurs in
capillaries in essential hypertension (Lack et al, 1949; Landau & Davis, 1957; Harper
et al, 1978) is not present in subjects predisposed to high blood pressure, and is
therefore unlikely to be of pathogenic importance. However, in the present study the
structure of larger arterioles was not examined directly. The absence of any difference
in minimum forearm vascular resistance suggests that luminal narrowing does not
occur in skeletal muscle in subjects predisposed to high blood pressure. However,
there is a substantial contribution to minimum dermal vascular resistance from larger
arterioles (Shore & Tooke, 1994), and I cannot exclude the possibility that luminal
narrowing in these vessels contributes to the marked differences in dermal vascular
resistance observed.
The mechanism of capillary rarefaction may be either structural, associated with
capillary attrition or with impaired angiogenesis, or functional, associated with
impaired recruitment of non-perfused capillaries during stimulation (Prewitt & Wang,
1991). In subjects with a familial predisposition to high blood pressure, rarefaction is
structural, since basal capillary numbers were not significantly different but recruitment
of capillaries during venous occlusion was markedly impaired in HF offspring. Thus,
structural capillary rarefaction is associated with almost maximal recruitment of
capillaries in the basal state so that the incremental functional change with venous
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occlusion is smaller. The observation that a smaller proportion of capillaries are non-
perfused in the basal state in subjects with a familial predisposition to high blood
pressure raises the possibility that their microvessels are exposed to higher systemic
perfusion pressures for longer periods than normal. In due course this may promote
the microvascular pathology which develops with essential hypertension.
If the capillary rarefaction observed is structural then it may be explained by impaired
angiogenesis. This is one hypothesis used to explain the relationships between adult
hypertension and growth in intra-uterine life, childhood, and puberty (Lever & Harrap,
1992). Of particular interest is the observation that hypertensive patients, and the
offspring with high blood pressure irrespective of parental blood pressure (Table 6.1
and Watt et al, 1992), tend to have a higher body mass index despite the
epidemiological data that they start life smaller than their normotensive peers (Barker et
al, 1990). It may be that, because of faster rates of 'catch-up' growth in later life,
hypertensive subjects out-grow their vascular tree, thereby having to recruit more
capillaries to continuous perfusion resulting in accelerated structural microvascular
changes and hypertension. Although HF subjects had the lowest birth weights, this
result was not statistically significant. Further, LNF subjects had comparably low birth
weights, and it may be that this is dictated more by parental than by offspring blood
pressure. However, in epidemiological terms, the numbers of offspring studied were
extremely small, and it is likely that there was insufficient power to draw useful
conclusions. Birth weight is only one variable in Barker's equation. A pilot study was
performed to obtain placental weights from maternity records for the 105 offspring
who took part in this study. However, due to poor archiving, it was impossible to
obtain placental weights.
In summary, this study shows that capillary rarefaction and impaired microvascular
vasodilatation are associated with familial predisposition to essential hypertension in
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young adult males, and are not features of increased blood pressure per se. In contrast,
capillary luminal diameter and blood flow are not deranged at this stage of the natural
history of the disease, and these are more likely to be consequences rather than causes
of hypertension. Thus, the mechanisms dictating microvascular growth and anatomy






DYSLIPIDAEMIA, which predisposes individuals to atherosclerosis, and hypertension,
which accelerates atherosclerotic vascular disease, are major causes of morbidity and
mortality in the industrialised world. Being able to recognise which hypertensive
and/or hypercholesterolaemic individuals are at high risk of developing clinically
significant target organ damage would be useful to their clinical management, and to
determining their prognosis. The few studies which have used arterial infusion
techniques to assess dysfunction of the vascular endothelium in essential hypertension
and hypercholesterolaemia, have not produced data on a large enough scale to allow
conclusive epidemiological interpretation. For example, some patients with essential
hypertension do not show an impairment in endothelial function as judged by the
acetylcholine test (Cockcroft et al, 1994). Hypertension has a multi-factorial aetiology
(Chapter 6), and it may be that certain sub-populations of patients are more at risk than
others of developing target organ damage.
With this in mind, a major aim of this thesis was to validate the non-invasive technique
of iontophoresis for assessing endothelial function, so that larger groups of patients
could more easily be studied. Although this aim may now appear to have been
ambitious, some important information on the pharmacological mechanisms of
microvascular function has, nevertheless, emerged.
An intact endothelium is necessary for the maintenance of vascular tone and the
regulation of blood pressure (Chapter 2). Inhibition of basal generation of nitric oxide
by L-NMMA caused an increase in blood pressure and peripheral vascular resistance.
The blood vessels contributing to these effects are likely to be microvessels as these
make the greatest contribution to peripheral resistance, and the purpose of Chapters 3-5
was to investigate the existence of functional microvascular defects and to establish
their pharmacological mechanisms.
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It would appear that nitric oxide plays a more important role in the regulation of
arteriovenous anastomotic flow in the skin microcirculation than in nutritive flow
(Chapter 3). Therefore, the role of nitric oxide may be related to the function of the
tissue being investigated, as well as to the size of vessel (see the Discussion section
(Section 3.4) in Chapter 3).
In Chapter 4, using transdermal iontophoresis of acetylcholine in the presence of
aspirin, the investigation of endothelial function in forearm dermal microvessels
showed that the principal mechanism of vasodilatation in nutritive tissue (volar surface
of forearm) was prostanoid-mediated. With this established in healthy individuals, the
next logical step was to examine whether any alterations occurred in patients with
known endothelial dysfunction as assessed by the 'gold standard' arterial infusion
technique, and this was the subject of Chapter 5. An impaired response to
acetylcholine in dermal vessels of hypercholesterolaemic patients was only observed in
the presence of aspirin, suggesting enhanced generation of vasodilator prostanoids, or
reduced generation of other mediators of vasodilatation in these subjects. Thus, under
resting conditions of blood flow, use of iontophoresis for direct detection of
endothelial dysfunction (as impaired nitric oxide generation) would not seem
appropriate. However, hypercholesterolaemic patients also showed an impaired
sodium nitroprusside response in dermal vessels (with or without aspirin), suggesting
reduced sensitivity of vascular smooth muscle to nitric oxide. This might explain the
importance of vasodilator prostanoids in effecting vasodilatation in these vessels.
Iontophoresis may be more useful, therefore, in assessing vascular smooth muscle
sensitivity in the dermis.
Previous theory for the structural basis of increased peripheral resistance characterising
essential hypertension, has concentrated on increased arterial walklumen ratio
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(Folkow, 1958). However, the results from Chapter 6 suggest microvascular
rarefaction as an alternative explanation for increased resistance. The structural defect
of rarefaction (Chapter 6) appears to be causal as it is associated with familial
predisposition to essential hypertension in young adult males. In contrast, capillary
luminal diameter and blood
, flow do not appear abnormal at this stage in the
pathogenesis of hypertension, and these are likely to be consequences rather than
causes of the disease. Functional abnormalities were not demonstrated in the young
people studied in Chapter 6. These young people did not have the clinical diagnosis of
essential hypertension, but in due course structural rarefaction may promote the
microvascular pathology which develops with essential hypertension. Therefore,
functional abnormalities, particularly endothelial dysfunction as discussed above, may
be only part of the aetiological profile, and shoud not be seen in isolation in a
heterogeneous disorder (Luscher, 1992). The mechanisms dictating microvascular
growth and anatomy deserve more detailed attention in future studies as possible
candidate mechanisms in the pathogenesis of hypertension.
In atherosclerosis, endothelial dysfunction is secondary to the damaging effects of
hypercholesterolaemia, particularly to oxidised LDLs (Chapter 5), a process which is
accelerated by hypertension. In turn, if the endothelium cannot produce the correct
balance of agents required to neutralise oxLDLs and oxygen free radicals, and to
prevent thrombus formation (Chapter 5), this may lead to the structural damage of
atheromatous plaque formation, ultimately contributing to the risk of coronary heart
disease and stroke. Therefore, functional and structural defects are not separate entities
providing risk, but interact in different ways to produce the occlusive vascular disease
of hypertension (hypertrophy) and hypercholesterolaemia (atheroma). The mechanisms
by which hypertension induces lesions of atherosclerosis are poorly understood
(Chapter 1), and investigation of angiogenic factors involved in genesis of
atherosclerosis also deserves further attention.
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